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ABSTRACT 
 
Advanced imaging techniques are being increasingly utilized as quantitative 
biomarkers and outcome parameters to identify and monitor disease and evaluate new 
treatments.  Validation of these techniques in animal models is imperative to reliably 
interpret results and apply them clinically in humans.  Studies reported here utilized 
computed tomography (CT) and magnetic resonance imaging (MRI) to characterize the 
sheep model of fetal alcohol spectrum disorders (FASD) and the golden retriever (GRMD) 
model of Duchenne muscular dystrophy (DMD).  Objective biomarkers are necessary to 
help identify some children with (FASD) who do not demonstrate the facial 
dysmorphology criterion for diagnosis.  The sheep model of first trimester binge alcohol 
exposure was used to study the utility of CT and MRI to distinguish disease.  Based on 
CT assessment, total skull bone volume was significantly more sensitive than cranial 
circumference in identifying 6-month-old lambs exposed to binge alcohol.  Poor nutrition 
may also contribute to adverse developmental outcomes of prenatal alcohol exposure and 
choline supplementation has shown benefit in rodent models.  Magnetic resonance 
imaging (MRI) was used to study the brains of 6-month-old lambs from alcohol-exposed 
pregnant sheep supplemented with and without choline throughout pregnancy.  Total brain 
volume in lambs was reduced regardless of choline supplementation.  Duchenne muscular 
dystrophy (DMD) is an X-linked disease caused by mutations in the dystrophin gene.  
Therapies for DMD must be assessed using objective biomarkers such as MRI to 
document potential benefit.  The lack of studies correlating MRI indices and 
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histopathologic lesions has limited interpretation.  The pectineus muscle from GRMD 
dogs was used to register and correlate histology with MRI using a novel registration 
technique, compare histology segmentation between Aperio and a custom algorithm for 
automated histomorphometry, and compare metrics between 4.7T and 3T scanners.  We 
found that histology and MR images co-registered but metrics were poorly correlated.  
Aperio and the custom algorithm had similar results and with optimization, it could be 
applied to the current research.  Only T1 values were correlated between MRI scanners 
but neither T1 values, nor any of the 3T metrics correlated with histologic segmentations.  
Multiple imaging modalities outlined in this dissertation show the usefulness of objective 
quantitative techniques that could be adapted and applied to any disease entity.    
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CHAPTER I  
INTRODUCTION  
 
I.1 History of magnetic resonance imaging (MRI) 
MRI has advanced tremendously since it was first used clinically over 30 years 
ago with it now being a primary diagnostic modality commonly found in a majority of 
medical clinics, hospitals, and research institutions around the world.  The first clinical 
scanner was used in the early 1980s but the history of MRI dates back some 40 years 
before that when Isidor Isaac Rabi described nuclear magnetic resonance (NMR).  Rabi 
developed a way to measure the magnetic characteristics of atomic nuclei and was 
awarded a Nobel Prize in Physics in 1944.  Two other physicists, Felix Bloch and Edward 
Purcell, independently observed NMR in solids and liquids earning them a shared Nobel 
Prize for Physics in 1952 [1, 2].  Erwin Hahn developed spin echo in 1950 [3] while in 
1966 Richard Ernst developed Fourier transform NMR spectroscopy, earning a Nobel 
Prize in Chemistry in 1991 for his contributions [4].  Raymond Damadian made an 
exciting discovery in 1971 when he utilized NMR to evaluate T1 and T2 relaxation times 
in rat tumors, finding tumor tissue had longer T2 times [5].  The foundation for MRI as 
we know it today was ultimately laid by Paul Lautebur and Peter Mansfield when they 
independently described magnetic field gradients to localize NMR signals, and their 
contributions earned a shared Nobel Prize in Physiology/Medicine in 2003 [6, 7].  
Following this important ground work, Damadian produced the first MR images of the 
human thorax in 1977 while Mansfield and Maudlsey imaged a human finger [8].  During 
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the next three years, the human wrist, abdomen, head, and body were all scanned [9-12] 
and the first commercial scanner was released in 1983 by General Electric and Siemens.  
In the late 80s, Michael Moseley developed techniques in diffusion imaging with fMRI 
[13, 14] and Le Bihan et al. continued that work with diffusion coefficients [15] eventually 
leading to diffusion tensor imaging (DTI) and blood oxygenation level-dependent (BOLD) 
methods in 1990 [16, 17].   
Since the early 90s, there is an ever growing number of techniques that are being 
developed and techniques currently in use that far exceed the rudimentary scans done in 
early investigations as described above.  Each year there are thousands of publications that 
outline new techniques, methods for analysis, and advancements in the imaging field.  
Importantly, we are now evaluating MRI as an outcome biomarker for pre-clinical 
research because it is non-invasive and it provides objective and quantifiable outputs.  
Studies outlined in this dissertation demonstrate the immense potential that MRI holds in 
clinical evaluations, therapeutic development, and future research in two entirely different 
disease entities, fetal alcohol spectrum disorders (FASD) and Duchenne muscular 
dystrophy (DMD).      
I.1.1 Magnetic resonance imaging (MRI) for brain scans in fetal alcohol spectrum 
disorders (FASD)  
Fetal alcohol spectrum disorders (FASD) is an umbrella term that encompasses a 
full range of effects resulting from prenatal exposure to alcohol, with fetal alcohol 
syndrome (FAS) being the most severe [18].  Over a span of nearly 20 years, binge 
drinking among pregnant women has not significantly declined [19] and in the United 
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States, FASD is a leading cause of preventable birth defects and developmental disorders 
[20].  Because FASD is still a problem today, MRI has become one of the leading 
diagnostic tools in identifying children with abnormalities.      
For the first time in 1992, two children with fetal alcohol syndrome were imaged 
with MRI and structural abnormalities in the brain were reported [21].  Prior to this time, 
abnormalities had been reported but they were primarily based on postmortem 
examination in infants [22].  This discovery has led to numerous reports in both humans 
and animals documenting brain changes related to alcohol exposure.  One of the most 
consistent findings in studies of FASD is an overall volumetric reduction [23-28] as well 
as global decreases in brain volume [25, 29].  More focused studies have documented 
abnormalities in the corpus callosum that include volume reductions [30], shape changes 
[31-33], complete [24, 30, 34] and partial agenesis and hypoplasia [21, 24, 35, 36].  The 
cerebellum is another target of alcohol exposure with reports of decreased volume and 
surface area [21, 25, 35] increased sensitivity in the anterior vermis [35, 37], and 
hypoplasia [36].  Since the cerebellum is involved with motor function and attention 
regulation, deficits in attention [38], balance [39], coordination [40, 41], verbal learning, 
and memory [42] may be related to increased sensitivity in this part of the brain.  The basal 
ganglia is also a target of alcohol, specifically causing volume reductions in the caudate 
nucleus [21, 25].  This portion of the brain has been tied to verbal learning and recall and 
could account for deficits in affected children [43].  Abnormal brain networks in this 
portion of the brain can result in behavioral changes, deficits in executive functioning [44, 
45] and also connections to the motor cortex [46] associated with coordination [41, 47] 
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and fine motor skills [48, 49].  The hippocampus is another structure commonly studied 
in FASD but some studies have reported a reduced volume [35, 50] while others report 
that the hippocampus is spared [25].  Joseph et al. recently showed shape variations in the 
hippocampus associated with prenatal alcohol exposure [51].  A recent study found that 
moderate alcohol doses administered in a binge like pattern throughout gestation fail to 
alter cell numbers in the hippocampus and the olfactory bulb and that high exposure during 
the third trimester is required for injury [52].  Finally, whole brain studies have revealed 
that heavy prenatal alcohol exposure results in increased gray matter and relatively less 
white matter as well as thicker cortices [29, 53, 54].  Children with thinner cortices showed 
increased verbal performance [55] and intellectual function [56] while the FASD group 
had signs of immature brain development.    
As evidenced from the literature above, it is clear that prenatal alcohol exposure 
affects a large number of structures in the brain thus making it a focus in research with 
imaging modalities like MRI.  Volumetric reductions are often used as biomarkers but as 
potential treatments and interventions are developed, animal model mechanistic studies 
are imperative to control for population and alcohol exposure differences often seen in 
human studies.  The ovine model offers significant benefits over the mouse, most notably 
with in utero brain development more closely tracking with humans [57].  Also, there are 
a vast number of new techniques and imaging technologies first used in fetal alcohol 
research over the last decade that need to be critically evaluated in animal models if they 
will be used as biomarkers, like diffusion tensor imaging (DTI) [26, 58-61], magnetic 
resonance spectroscopy (MRS) [62-64], single photon emission computed tomography 
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(SPECT) [34, 50, 65], positron emission tomography (PET) [66], and functional magnetic 
resonance imaging (fMRI) [27, 67-72].  The study outlined in chapter III of this 
dissertation utilizes MRI and quantitative techniques to evaluate the brain when a 
therapeutic intervention is introduced. 
I.1.2 Magnetic resonance imaging (MRI) for skeletal muscle scans in Duchenne 
muscular dystrophy (DMD)  
Duchenne muscular dystrophy (DMD) is an X-linked progressive degenerative 
skeletal muscle disease that affects 1: 3,500 boys and results from mutations in the 
dystrophin gene [73].  Boys are typically diagnosed with DMD between 3-5 years of age, 
they are wheelchair bound by their early teens and they often die from cardiopulmonary 
complications between 20-30 years old.  Despite our detailed knowledge of dystrophin 
and scientific advancements over the last thirty years, there is no cure for DMD.  Non-
invasive methods such as MRI are crucial in monitoring disease progression and in 
determining the efficacy of new treatments as they are developed and tested. 
MRI was first used in 1986 to analyze and compare normal patients to patients 
with pathologic skeletal muscle disease, including DMD [74].  This study and numerous 
others that followed showed that MRI had the capability to distinguish structure and 
composition changes in the skeletal muscle of DMD patients [75-78].  Qualitative skeletal 
muscle assessment initially used T1 weighted images and post contrast imaging to identify 
structure defects [77-80].  T1 values in DMD are typically high early in the disease and 
then the values decline as the disease progresses and also as the muscle are replaced with 
fatty deposits [78].  In a study evaluating nine skeletal muscles, eight muscles had a 
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significant difference in the T1 weighted signal intensities when DMD patients treated 
with steroids were compared to healthy controls [81].  Garrood et al. also showed that 
gadolinium enhancement was increased in the tibialis muscles of DMD patients doing 
exercise and that the T2 values in thigh muscles were significantly higher than normal 
controls.  Eight out of nine muscles also showed an increase in T1 weighted signal 
intensity in DMD patients compared to normal, suggestive of fat infiltration [81]. 
Muscle cross sectional area is another technique used in quantitatively evaluating 
DMD.  This technique measures individual muscles traced on axial slices from T1 
weighted images.  Mathur et al. found that the cross sectional area in the posterior calf 
muscles were greater (~60%) in DMD boys compared to normal controls but the tibialis 
and quadriceps were not significantly different.  Additionally, DMD boys under the age 
of ten had a larger cross sectional areas in the quadriceps compared to controls but this 
cross sectional area became smaller as the boys got older (>10 years old) and the disease 
progressed [82].  Another studied evaluated the proportion of contractile skeletal muscle 
to non-contractile tissue in DMD boys and found that proportions of non-contractile tissue 
were greater compared to controls and non-contractile tissue also increased with age.  This 
proportion of non-contractile tissue also correlated with several functional tests (rise from 
floor, timed 30 ft. walk, ascending steps) [83].  T2 weighted images are also valuable in 
evaluating DMD and have been shown to reflect muscles changes associated with damage, 
inflammation and fat infiltration.  Kim et al. found that the T2 value from the gluteus 
maximus muscles was highly correlated to the non-quantitative MRI score for fat 
infiltration.  This T2 value also correlated with clinical measures including age, clinical 
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function scale, timed Gower score and time to run 30ft [84].  T2 values can also be used 
to map a region of interest longitudinally, and thus muscle heterogeneity can be monitored 
with disease progression [75].  Fat suppression sequences have also become important 
when evaluating DMD boys because early in the disease, the muscles are infiltrated with 
edema and inflammation versus fat later on.  Short-tau inversion recovery images (STIR) 
suppress the fat and allow extracellular water associated with edema and inflammation to 
become more definable.  Marden et al used STIR sequences and discovered that young 
boys lacking fatty infiltration had increased areas of signal intensity associated with edema 
and inflammation that would have otherwise been missed [77].   
The three-point Dixon technique is beneficial in studying DMD because it allows 
the signal intensities in each voxel of tissue to be separated into values for both fat and 
water.  This sequence produces high resolution maps for fat and water that allow fat to be 
quantified in individual muscles.  In a study of DMD boys, the three-point Dixon 
technique was used to quantify fat in the thigh muscles and the results showed that 
quantitative fat values correlated better with disease severity than strength measures [85].  
Magnetic resonance spectroscopy (MRS), proton spectroscopy (1H) and phosphorus (31P), 
has also been used to study muscles in DMD [86-88] and is beneficial in that it allows 
muscles metabolites to be evaluated [75].  Torriani et al. showed in a study of lower leg 
muscles in DMD boys that there is a distinct pattern of involvement and increased fat 
deposition that correlates with functional measures [87].  Hsieh et al. used MRS and found 
that boys with DMD have reduced trimethylamines to muscle total creatine ratio and that 
this correlates negatively with function [89].  In 2015, MRI with 1H-MRS and T2 maps 
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were used to evaluate 42 boys with DMD and 31 normal controls.  T2 maps were found 
to be more accurate than MRS in the gluteus maximus and vastus lateralis.  MRS fat 
fractions likely underestimate the actual fat because of the presence of edema associated 
with the disease [88].       
Diffusion weighted imaging (DWI) has also been used to evaluate muscle 
pathology and several reports show that DWI derived quantitative parameters can 
potentially be used as biomarkers or outcome measures [90, 91].  The apparent diffusion 
coefficient (ADC) has been shown to be elevated in inflammatory myopathies, with 
fractional anisotropy (FA) showing inconsistent results [92, 93].  In a DMD study, DWI 
parameters correlated with clinical and NMR markers for disease severity [90] but a 
longitudinal study has not been done.  Changes in ADC and FA in DMD are primarily due 
to the degree of fat infiltration.  In a recent study of DMD boys, an increase in ADC was 
identified in the tibialis muscle when the effects of fat and signal to noise were taken into 
account [94].     
 As evidenced above, MRI has become an important tool for studying muscle over 
the last two decades because it is non-invasive and readily available.  A majority of the 
reports listed above focus on several physiologic and pathologic events that take place in 
Duchenne muscular dystrophy that allow for visual changes on MRI including 1) muscle 
necrosis which leads to edema and inflammation, 2) continued cyclic damage which 
ultimately leads to fibrofatty infiltration, and 3) the eventual loss and atrophy of muscle 
mass.  The use of MRI in skeletal muscle is definitely not as refined as its use in the brain 
but as technology continues to advance, quantitative methods to identify outcome 
 9 
 
parameters in DMD will continue to be validated.  The techniques outlined in chapter IV 
of this dissertation are novel and to the author’s knowledge, have not been used in 
evaluating DMD.  
I.2 History of computed tomography (CT) 
Computed tomography wouldn’t exist today if it weren’t for the accidental 
discovery of radiation and ultimately X-rays by Wilhelm Conrad Röntgen in 1895 [95].  
His initial experiments were reported in the New York Times and by 1901 he was awarded 
the first ever Nobel Prize in physics for his discovery.  The world was fascinated with x-
ray pictures but E. Thompson was already trying to develop three-dimensional x-ray 
images using stereoscopic techniques.  Doctor Karol Meyer developed an early method 
resembling the process of scanning by computed tomography.  He obtaining stratigraphic 
images with a moving X-ray tube and stationary film cassette.  Carlo Baese patented a 
simultaneous moving tube and cassette in 1915.  Johann Radon published his work on 
“radon transform” in 1917 which was the mathematical basis of CT, explaining that 
density can be reconstructed.  Allesandro Vallebona implemented stratigraphy in the early 
1930s whereby the x-ray source and film detector were fixed to a pendulum.  Some of his 
theories were wrong but the helped lead to computed tomography.  In the mid-50s, Allan 
Cormack was interested in radiotherapy treatment so he developed a mathematical 
approach to solving problems with variations in body tissues.  He then moved to Harvard 
and worked on image reconstruction of x-ray projections and he built a tomographic 
device in 1963.  Independently of Cormack, Godfrey Hounsfield worked on the technical 
development of radar air defense systems.  Hounsfield began his research in tomography 
 10 
 
by initially using gamma radiation and he used the power of computers to solve the 
problem of image reconstruction.  This is how the term “computed” tomography came 
about.  The gamma ray source in early scanners had low output so some exposures took 
over nine days to complete.  The first image with enough detail to tell the difference 
between tissues of a formalin fixed brain took 2.5 hours to reconstruct and was 80 x 80 
pixels in resolution.  This device was patented in 1968.  In clinical testing, the gamma tube 
was replaced with an x-ray tube and scan time was shortened to nine hours with a 
reconstruction time of twenty minutes.  In 1971, the prototype scanner EMI Mark I was 
installed at Atkinson Morley’s Hospital with the help of neurologists James Ambrose and 
Louis Kreel [95].  The opening was only large enough to scan a head.  The first 
tomographic examination was of a woman with a suspected brain tumor.  The image 
produced made it possible to differentiate brain tissue from a developing cyst.  In 1972, 
Hounsfield formally presented his results and by the end of 1973 [96], the first commercial 
CT scanner was on the market, EMI CT 1000.  Advancements in the machine made it 
possible to acquire an image in 20 seconds and then the resolution was increased to 320 x 
320 pixels.  In 1979 both Cormack and Hounsfield were awarded the Nobel Prize for 
Physiology or Medicine.  Remarkable advancements have taken place since this time most 
notably the fan-beam (1976), spiral CT (1989), 4-slice spiral CT (1998), 8-slice spiral CT 
(2001), 16-slice spiral CT (2002), 64-slice spiral CT (2004), dual-source CT (2005), 320-
slice spiral CT (2007), high-definition CT (2008), and 640-slice spiral CT (2012).  
Additionally, the future of CT involves fusion imaging in which there is superimposition 
of images from two dependent imaging modalities to produce an image which provides 
 11 
 
greater information.  Examples are positron emission tomography (PET)-CT, single-
photon emission computerized tomography (SPECT)-CT, and CT-MRI.      
One of the benefits of CT is that it can be used for quantitative data collection and 
analysis on both bone and soft tissues in one scan.  Facial measures are routinely taken 
clinically in children suspected of prenatal alcohol exposure.  These same facial measures 
can be taken with CT by creating a 3D reconstruction of the face.  Additionally, the 
underlying bone can also be evaluated.  CT was used to evaluate both soft tissue and bone 
in the sheep model of FASD outlined in chapter II of this dissertation. 
I.2.1 Computed tomography (CT) and fetal alcohol spectrum disorders (FASD) 
There are currently no published studies that utilize computed tomography in 
FASD.  A major downside in CT imaging involves concerns over radiation exposure 
leading to CT technology and manufacturers claiming to generate the desired image with 
the lowest radiation dosage for particular studies.  The “Alliance for Radiation Safety in 
Pediatric Imaging” initiated a campaign called “Image Gently” with goals to reduce 
radiation exposure in children by amending adult protocols.  Additionally, the benefit 
gained from imaging needs to exceed the overall risk.  It is likely that because of this 
campaign, the study outlined in chapter II of this dissertation would not be clinically 
applicable at this time.  However, as computer and CT technology advance, the benefit of 
scanning a child with fetal alcohol spectrum disorders will far outweigh the risk and the 
techniques explained in this dissertation will have already been validated in an animal 
model.         
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CHAPTER II  
COMPUTED TOMOGRAPHY ASSESSMENT OF PERIPUBERTAL 
CRANIOFACIAL MORPHOLOGY IN A SHEEP MODEL OF BINGE 
ALCOHOL DRINKING IN THE FIRST TRIMESTER*  
 
II.1 Overview 
Identification of facial dysmorphology is essential for the diagnosis of fetal alcohol 
syndrome (FAS), however, most children with fetal alcohol spectrum disorders (FASD) 
do not meet the dysmorphology criterion.  Additional objective indicators are needed to 
help identify the broader spectrum of children affected by prenatal alcohol exposure.  
Computed tomography (CT) was used in a sheep model of prenatal binge alcohol exposure 
to test the hypothesis that quantitative measures of craniofacial bone volumes and linear 
distances could identify alcohol-exposed lambs.  Pregnant sheep were randomly assigned 
to four groups: heavy binge alcohol, 2.5 g/kg/day (HBA); binge alcohol, 1.75 g/kg/day 
(BA); saline control (SC); and normal control (NC).  Intravenous alcohol (BA; HBA) or 
saline (SC) infusions were given three consecutive days per week from gestation day 4-
41, and a CT scan was performed on postnatal day 182.  The volumes of eight skull bones, 
cranial circumference, and 19 linear measures of the face and skull were compared among 
treatment groups.  Lambs from both alcohol groups showed significant reduction in seven 
of the eight skull bones and total skull bone volume, as well as cranial circumference.  
 
 
 
*Reprinted with permission from “Computed tomography assessment of peripubertal craniofacial morphology in a sheep model of 
binge alcohol drinking in the first trimester” by Birch SM, Lenox MW, Kornegay JN, Shen L, Ai H, Ren X, Goodlett CR, Cudd TA, 
Washburn SE, 2015.  Alcohol, 49(7): 675-89, Copyright © 2015 by Elsevier Inc.    
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Alcohol exposure also decreased four of the 19 craniofacial measures. Discriminant 
analysis showed that alcohol-exposed and control lambs could be classified with high 
accuracy based on total skull bone volume, frontal, parietal or mandibular bone volumes, 
cranial circumference, or interorbital distance.  Total skull volume was significantly more 
sensitive than cranial circumference in identifying the alcohol-exposed lambs when 
alcohol-exposed lambs were classified using the typical FAS diagnostic cutoff of <10th 
percentile.  This first demonstration of the usefulness of CT-derived craniofacial measures 
in a sheep model of FASD following binge-like alcohol exposure during the first trimester 
suggests that volumetric measurement of cranial bones may be a novel biomarker for 
binge alcohol exposure during the first trimester to help identify non-dysmorphic children 
with FASD.   
II.2 Introduction 
 The teratogenic effects of alcohol abuse during pregnancy were formally identified 
as fetal alcohol syndrome (FAS) about four decades ago [97].  FAS is diagnosed primarily 
based on three criteria: 1) presence of at least two of three characteristic dysmorphic facial 
features (smooth philtrum, thin upper lip, and short palpebral fissures); 2) growth deficits 
in height and/or weight; and 3) structural, neurologic, or functional central nervous system 
(CNS) abnormalities [98, 99].  It is now recognized that the large majority of children with 
untoward effects from prenatal alcohol exposure do not fully meet the criteria for a 
diagnosis of FAS, but still express a broad range of skeletal, neurological, developmental, 
behavioral or learning abnormalities [100-102].  In 2004, the designation fetal alcohol 
spectrum disorders (FASD) was adopted as an umbrella term to encompass the full range 
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of effects resulting from prenatal exposure to alcohol, with FAS being the most severe 
[18]. 
In the United States, FASD is a leading cause of preventable birth defects and 
developmental disorders [20] with a prevalence ranging from 1% of all births [103, 104] 
to as high as 2-5% [105].  FASD places a large burden on the economy, with estimates of 
the cost as high as $4 billion annually due to health care, lost productivity, and special 
education [103, 106].  Despite extensive efforts to inform the public about the risks of 
alcohol use during pregnancy, 7% of approximately half a million pregnant women 
surveyed had consumed alcohol in the previous 30 days and 1.4% reported binge drinking 
[107].  Over a span of nearly 20 years, binge drinking among pregnant women has not 
significantly declined [19].   
Optimal management of children with FASD depends on accurate identification 
of the full spectrum of children adversely affected by prenatal alcohol exposure.  
Diagnosis of FAS through clinical screening relies on trained recognition or 
anthropometric measurements of dysmorphic features of soft tissue structures of the face, 
yet children with FAS constitute fewer than 10% of all children with FASD.  Reliable 
indicators of adverse effects of prenatal alcohol exposure are needed to help identify the 
much larger number of children with FASD who do not meet the facial dysmorphology 
criterion.  Quantitative analysis of craniofacial bones, which are derived from embryonic 
neural crest cells that are sensitive to alcohol exposure during neurulation [108], provides 
a potential approach for identifying a more sensitive indicator.  Relatively little work has 
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been done to evaluate the underlying craniofacial bones, and its potential use as a 
quantitative indicator to identify children with FASD is largely untapped. 
Binge drinking during the first trimester (including prior to pregnancy recognition) 
is the most common pattern of risk drinking in women of childbearing age [109-111].  
Craniofacial bone changes are an appropriate candidate as a structural biomarker for binge 
drinking, in part because of the spatiotemporal links between embryonic CNS and 
craniofacial development during the first trimester.  Bones that form the neurocranium 
(frontal, parietal, and occipital bones) are derived principally from the neural crest and 
paraxial mesoderm, whereas bones that form the viscerocranium (mandible, maxilla, 
nasal, lacrimal, and jugal bones) originate primarily from the first two pharyngeal arches 
[112].  During neurulation, neural crest cells originate at the junction of the neural folds 
and eventually the cells migrate to various locations throughout the embryo to form body 
structures [108].  A subset of neural crest cells, cranial neural crest cells, form structures 
of the face (bones, cartilage, and cranial nerves) [113], and are highly sensitive to alcohol.  
Damage to these cells results in dysmorphic craniofacial features and some associated 
brain abnormalities associated with FAS [114-116].     
In humans, key events over the first trimester of pregnancy [117] include 
neurulation (spanning post fertilization days 22-31) which involves formation of the 
neural tube and neural crest, with anterior neuropore closure by day 30.  Emergence of the 
full five vesicle stage is evident at five weeks, along with formation of the pontine flexure, 
optic cup and nasal pit.  Formation of the telencephalic cortical plate begins at 7-8 weeks 
with the appearance of the five zones of the emerging cerebral cortex (marginal, cortical 
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plate, subplate, subventricular and ventricular zones). By comparing the timing of the 
same events during embryonic development in sheep (that have a 147 day gestation), it is 
possible to establish temporal equivalence in sheep to the first eight weeks of human 
development.  In sheep, neural tube formation extends into the third gestational week and 
the anterior neuropore closes by gestational day (GD) 21.  The five vesicle stage is evident 
in the fourth gestational week, while the cortical plate begins forming in the lateral wall 
of the telencephalon at GD35.  By GD40, the lateral wall has formed a defined cortical 
plate and the five zones of the emerging cerebral cortex are evident [118].  Comparatively, 
the first forty days of embryonic development in the sheep is roughly equivalent to the 
first eight weeks of human development.   
Experimental animal models, primarily mouse models, have shown that binge-like 
alcohol exposure during the first trimester equivalent is sufficient to induce abnormal 
craniofacial development.  These studies have identified key roles of dose and timing of 
prenatal alcohol exposure in producing craniofacial effects that model some of those seen 
in FAS [113, 119].  Specifically, they have shown quantitatively that measurable 
craniofacial changes do occur [120-123].  A major goal of the current study was to extend 
this approach to a well-defined sheep model of binge alcohol exposure during a portion of 
the first trimester equivalent, to assess whether quantitative analyses of craniofacial bone 
volumes using computed tomography (CT) in six-month-old (peripubertal) lambs could 
accurately predict exposure. 
In this study, sheep were evaluated at six months of age because we wanted a target 
age comparable to middle school-aged children about to enter puberty during early 
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adolescence.  Sheep reach puberty when they attain 50-70% of their mature body weight, 
typically between 7-8 months of age, depending on breed [124].  Therefore, the 
developmental status of these lambs may be analogous to children in their middle school 
years with undiagnosed FASD that have developmental, behavioral, and/or learning 
deficits often identified by educators. Additionally, we sought to compare the relative 
accuracy of classifications of prenatal alcohol exposure through a single CT scan which 
allowed measurement of both cranial bone volumes and linear distance measures taken 
from bone (cranial) and soft tissue (facial) landmarks, along with cranial circumference.  
If confirmed, these quantitative approaches in this sheep model could provide new indices 
of the effects of prenatal alcohol exposure that may prove more sensitive than traditional 
FAS diagnostic indices (head circumference; facial morphometrics).  This could translate 
into improved identification of children with FASD.   
Measures evaluated in the current study include the volume of the bones of the 
neurocranium and viscerocranium, along with linear measurements of the skull, face, and 
cranial circumference.  CT was utilized because it is non-invasive, readily available in 
most hospitals, produces high-resolution, three-dimensional images and one scan allows 
measurement of bony and soft tissue structures of the face.  CT has been effectively used 
to study fixation artifacts in embryologic studies [125] and recently in studies of 
craniofacial dysmorphology in mouse models of FASD [126, 127].  Repeated weekend 
binge drinking (3 consecutive days per week) over the first eight weeks of human 
pregnancy was modeled from GD4-41 in the sheep with two binge-like alcohol treatments.  
The first treatment modeled heavy binge drinking (2.5 g/kg per day, peak blood alcohol 
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concentrations (BACs) above 250 mg/dl) and the second treatment modeled more typical 
binge drinking (1.75 g/kg per day, peak BACs around 200 mg/dl).  We hypothesized that, 
relative to the control groups, lambs given binge-like prenatal alcohol exposure would:  1) 
have reduced CT-derived volumes of the skull bones; 2) have reduced cranial 
circumferences; 3) have altered craniofacial morphometrics of bone as well as face; and 
4) be classified accurately in terms of prenatal alcohol exposure based on one or more of 
these measures.  Because FAS is often associated with binge drinking during the first 
trimester, comparisons between the two binge treatment conditions could help determine 
whether more intense binge exposure episodes produce increasingly severe effects on 
craniofacial morphometrics or skull bone volumes.  
II.3 Materials and methods 
II.3.1 Animals 
All animals and experimental procedures were approved by the Institutional 
Animal Care and Use Committee (IACUC) at Texas A&M University.  Prior to breeding, 
Suffolk ewes (aged 2-5 years) received multi-species Clostridium bacterin-toxoid 
(Covexin 8, Intervet/Schering-Plough Animal Health, Summit, NJ) 2 ml intramuscularly, 
albendazole (Valbazen Suspension 7.5 mg/kg, Pfizer Animal Health, New York, NY) 0.75 
ml/25 lb of body weight orally, and ivermectin (Ivomec Drench for Sheep 0.8%, Merial, 
Duluth, GA) 3 ml/26 lb body weight orally.  The day of mating (the day that the ewes 
were marked by the ram) was designated as GD 0, and ewes entered the experiment the 
next day.  Ewes were penned individually for the experiment but had visual contact at all 
times with herd mates in adjacent pens in an environmentally regulated facility (22°C and 
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a 12:12 light/dark cycle).  Ewes entering the experiment were randomly assigned to one 
of four treatment groups:  normal control (NC), saline control (SC), binge alcohol (BA), 
or heavy binge alcohol (HBA).  Pregnancy was confirmed ultrasonographically on GD 25, 
and if ewes were not pregnant, they were removed from the experiment.  Ewes were fed a 
“complete” ration (TAMU Ewe Ration, Nutrena, Cargill, Minneapolis, MN) designed to 
meet 100% NRC requirements as calculated by ARIES (software version 2007, University 
of California, Davis) and had free access to drinking water.  Maternal food consumption 
was monitored daily.  All subjects consumed all feed offered. 
Just before parturition, ewes were moved to a covered pen outside where they 
lambed naturally.  At birth, newborn lambs were weighed and measured, and their navels 
were dipped in iodine (VetOne Stronger Iodine, 7%, MWI, Meridian, ID).  They were also 
given oxytetracycline (Liquamycin®, LA-200®, 200 mg/ml, Pfizer Animal Health, New 
York, NY) 1 ml intramuscularly and selenium/vitamin E (BO-SE®, 1 mg/ml, 
Intervet/Schering-Plough Animal Health, Summit, NJ) 0.5 ml subcutaneously.  Each ewe 
was checked for satisfactory milk production, and lambs were closely monitored for 
nursing, weight gain, and health status over the next two months.  At one and two months 
of age, lambs were vaccinated using multi-species clostridium bacterin-toxoid (Covexin 
8, Intervet/Schering-Plough Animal Health, Summit, NJ) 2 ml intramuscularly.  Nursing 
lambs and ewes remained together until the lambs reached two months of age, at which 
time they were separated from their mothers and weaned.  Ewes were removed from the 
premises, and weaned lambs remained in the same outdoor covered pens for the rest of the 
study.  At weaning, lambs received moxidectin (Cydectin® Oral Drench for Sheep 0.1%, 
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1 mg/ml, Boehringer Ingelheim, St. Joseph, MO) 0.2 ml/kg body weight orally, amprolium 
(Corid® 9.6% Oral Solution, Merial, Duluth, GA) 0.5 ml/kg orally once daily for 10 days, 
and vitamin B1 (Thiamine Hydrochloride, 500 mg/ml, Rafter 8 Products, Calgary, 
Alberta, Canada) 1.5 ml subcutaneously once daily every third day for a total of four 
treatments.  Weaned lambs were fed a “complete” ration (Ringmaster Start-To-Finish 
Show Lamb Pellets, Nutrena, Minneapolis, MN) designed to meet 100% NRC 
requirements as calculated by ARIES (software version 2007, University of California, 
Davis) and had free access to drinking water.  At six months of age, lambs were euthanized 
using sodium pentobarbital (Beuthanasia®, Intervet/Schering-Plough Animal Health, 
Summit, NJ) 75 mg/kg intravenously.  Computed tomography (CT) imaging was 
performed immediately after euthanasia.   
II.3.2 Treatment groups 
Ewes (n=36) were randomly assigned to one of four treatments - normal control 
(NC) group (n = 8 ewes), the saline control (SC) group (n = 8 ewes), the binge alcohol 
(BA; 1.75 g/kg) group (n = 8 ewes), and the heavy binge alcohol (HBA; 2.5 g/kg) group 
(n = 12 ewes).  An intravenous catheter (16 ga., 5.25 inch Angiocath™; Becton Dickinson, 
Sandy, UT) was placed into the jugular vein of each ewe (except for the NC group) on GD 
4.  Beginning on this day, alcohol (2.5 or 1.75 g/kg body weight) or saline was 
administered intravenously over a 1-hour period via a pump (VetFlo® 7701B IV Vet 
Infusion Pump, Grady Medical, Temecula, CA). The alcohol solution was prepared by 
adding 95% ethanol to sterile 0.9% saline to achieve a 40% w/v alcohol solution.  
Solutions were prepared under aseptic conditions and were passed through a 0.2 μm 
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bacteriostatic filter. The saline control group received an infusion of isotonic saline (0.9%) 
that was equal in volume to the alcohol infusions.  Infusions were administered on three 
consecutive days per week from GD 4-41, followed by four days without treatment (18 
treatments total).   Lambs produced from ewes in the four treatment groups that entered 
the imaging study included 8 NC lambs (1 female, 7 males), 8 SC lambs (4 females, 4 
males), 8 BA lambs (6 females, 2 males), and 12 HBA lambs (6 females, 6 males).   
II.3.3 Maternal blood alcohol concentration 
Blood was drawn from the jugular vein of each ewe one hour after alcohol 
infusions began to measure peak BAC as previously described [128].  A 20 μl aliquot of 
blood was collected in a microcapillary tube and transferred into a vial containing 0.6 N 
perchloric acid and 4 mM n-propyl alcohol (internal standard) in distilled water. The vial 
was tightly capped with a septum-sealed lid and stored at room temperature until analysis 
by headspace gas chromatography (Varian Associates model 3900, Palo Alto, CA) at least 
24 h after collection.  
II.3.4 Computed tomography imaging 
Images were acquired on a computed tomography (CT) scanner (Biograph mCT®, 
Siemens Medical, USA) that operated at 120 kVp and 300 mA maximum cube current.  In 
the standard mode of operation, the distance from the detector to the source was 
1.0856e+003 mm and source to subject distance was 595 mm.  The data collection 
diameter of the scan field of view (SFOV) was 500 mm, and the reconstruction diameter 
of the display field of view (DFOV) was 300 mm.  The matrix was 512 x 512, pixel size 
was 0.59 mm, slice thickness was 1 mm, and voxel volume was 0.348 mm3.  The image 
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acquisition was performed on animals immediately after euthanasia.  Before animal 
scanning, daily system calibration was performed for accuracy.  Long-term scanner 
maintenance was performed in compliance with the operating manual (Siemens Biograph 
mCT ® versions VG10A, VG21A, VG30A, VG40A, chapters 7 and 12). 
II.3.5 Image analysis 
Amira Software (Visage Imaging, Inc., San Diego, CA) was used for bone 
segmentation and acquisition of skull measurements and craniofacial measurements.  
After three-dimensional (3D) reconstruction of the head scan, bony tissues were 
segmented (identified) as previously described [126].  A threshold of 160 HU (Hounsfield 
Units) was used to complete all bony tissue segmentations and skull measurements, and -
350 HU was used for soft tissue facial measurements.  Amira Software to visualize soft 
tissue structures and underlying craniofacial bones and then manually extracted a total of 
29 measurements: 1) nine 2D skull craniofacial measurements (distance, mm): upper 
facial depth, lower facial depth, orbital height and width, minimal frontal width, bitragal 
width, bigonial width, interorbital distance, and nasal length (Table I and Figure I); 2) ten 
2D craniofacial soft-tissue measurements (distance,  mm): nasal width, nasal length, nasal 
bridge length, philtrum length, lower facial height, mid-facial depth, lower facial depth, 
palpebral fissure length, inner canthal width, and outer canthal width (Table I and Figure 
II); 3) eight 3D individual skull bone volumes plus total skull bone volume (volume; 
mm3): mandible, frontal, parietal, occipital, maxilla, nasal, lacrimal, and jugal bones 
(Figure III), with total skull the sum of all eight; and 4) 2D cranial circumference (distance, 
mm).  Though cranial circumference was obtained as part of the skull distance measures  
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Table I.  Craniofacial measurements and landmarks 
Figure Location Number Measurement 
1 Skull 1 Upper facial deptha 
  2 Lower facial deptha 
  3 Cranial circumference 
  4 Orbital heighta 
  5 Orbital widtha 
  6 Minimal frontal width 
  7 Bitragal width 
  8 Bigonial width 
  9 Interorbital distance 
  10 Nasal length 
2 Face 11 Nasal width 
  12 Nasal length 
  13 Nasal bridge length 
  14 Philtrum length 
  15 Lower facial height 
  16 Mid-facial deptha 
  17 Lower facial deptha 
  18 Palpebral fissure lengtha 
  19 Inner canthal width 
  20 Outer canthal width 
Numbers are keyed to Figures 1 and 2. 
a Both right and left side measurements were taken. 
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Figure I.  Normal control lamb skull.  Lateral, caudal, and dorsal 3D aspects of the skull shown as visualized with Amira 
Software (Visage Imaging, Inc., San Diego).  The 10 skull linear measurements obtained from each of the lamb skulls 
are shown as identified in Table I. 
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Figure II.  Normal control lamb face.  Rostral and lateral 3D aspects shown of the lamb face as visualized with Amira 
Software (Visage Imaging, Inc., San Diego).  The 10 face linear measurements obtained from each lamb are shown as 
identified in Table I.  The ears have been cropped from the image. 
 
 
 26 
 
in the lambs, it was separated from the craniofacial measures for the purposes of initial 
analyses.  This was done because head circumference is typically obtained separately from 
the dysmorphology exam in clinical settings as part of the diagnostic measures to identify 
children with FAS, and it is interpreted separately from facial dysmorphology [129].  All 
measurements were taken by one of the authors (SMB) who was blinded to the treatment 
groups.  To decrease measurement error, each measurement was repeated in triplicate with 
subsequent measures taken only if the first three measurements differed by >2mm.  In 
instances in which >3 measurements were taken, outliers >2mm were not used.  The 
nineteen 2D craniofacial measurements and the cranial circumference measurement were 
acquired utilizing a measurement tool in Amira.  The eight bones of the skull were 
manually segmented, and their volumes were calculated based on the segmentation results.  
For the bilateral linear measurements of the face and skull, preliminary analyses indicated 
there were no significant differences between the left and right sides, so only the left side 
of all bilateral measurements of the face and skull were used for subsequent analyses.  
Total skull bone volume was calculated by adding all of the individual bone segmentations 
together (left and right sides where applicable).  Ear measurements were not taken because 
the ears were inadvertently cropped in the CT output file.     
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Figure III.  Segmented normal control lamb skull.  Lateral and caudal 3D aspects shown of a normal lamb skull as 
visualized with Amira Software (Visage Imaging, Inc., San Diego).  The 8 bones segmented for bone volumes on each 
lamb skull are shown.  In the lateral view, only the right sided segmentation is visible.  Total skull bone volume was 
calculated by adding together the volume of all of the bone segmentations (left and right sides). 
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II.3.6 Statistical analysis 
Given the unequal numbers of males and females in the NC and BA groups and 
the low number of lambs of each sex across treatment groups overall, the power to detect 
potential sex differences was very limited.  The data was first screened for potential 
differences between males and females.  This was to determine whether the male and 
female data could be combined within groups for the purposes of statistical analysis 
without confounding the analysis of prenatal treatment.  The NC group had only one 
female and the BA group had only two males.  The within-group ranking of the data of 
those subjects was determined and each fell within the range of the majority sex of the 
group.  Therefore, the individual data did not skew the within-group distribution for any 
measure for either the NC or BA groups.  For the two groups with equal numbers of males 
and females (SC and HBA), a two-way analyses of variance (ANOVA) with sex and 
treatment as grouping factors was calculated.  None of the measures showed a significant 
main or interactive effect of sex, so the data of males and females were combined within 
groups for subsequent analyses of variance. 
Treatment effects on measurements of skull bone volumes, skull distances, face 
distances, and cranial circumference were first analyzed with one-way between-subjects 
ANOVA using Bonferroni-corrected alpha levels to set the significance level within each 
set of data.  Thus, for the nine skull bone volumes and nine skull distance measures, a 
Bonferroni-corrected alpha level of 0.0056 (= 0.05/9) was used for the nine univariate 
ANOVAs.  For the ten face distance measures, the Bonferroni-corrected alpha level was 
0.005 (= 0.05/10).  For cranial circumference, the alpha level was 0.05.  Measures that met 
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the Bonferroni-corrected alpha level on the univariate test were then analyzed using 
pairwise comparisons among the four treatments within each measure, and the multiple 
comparisons were corrected by the Holm-Sidak method (p < 0.05).  In addition, two 
different one-way between-subjects analyses of covariance (ANCOVA) were calculated 
for individual skull bone volumes.  The first included covaried total skull bone volume 
and sex, while the second were covaried cranial circumference and sex.  Separate 
ANCOVAs were also calculated for the facial and skull bone linear distances, covarying 
for cranial circumference and sex.  The main purpose of these covariance analyses was to 
determine the extent to which individual skull bone volumes (or craniofacial linear 
measures) could provide quantitative evidence of the effects of binge alcohol treatment 
beyond that which might be associated with reduced head size, as well as to control for 
any influences of sex differences.  This approach follows a publication that assessed 
similar measures in a prenatal mouse model [126].  To determine whether total bone 
volume provides a better identification of alcohol-exposed lambs than cranial 
circumference (akin to head circumference in FAS screening), the 10th percentile was 
calculated for each measure.  Each distribution, total skull bone volume and cranial 
circumference, from the NC and SC groups (not significantly different) was combined to 
form control distributions for each measure.  Lambs in the BA and HBA groups were then 
classified based on whether or not they were < 10th percentile of the control distribution 
for each measure (similar to the FAS screening cutoff).  The relative sensitivity of the two 
measures was determined by comparing the number of lambs in the 10th percentile of the 
two measures using Fisher’s Exact Test. 
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II.3.7 Discriminant analysis 
Univariate discriminant analyses of the craniofacial bone measures were examined 
for six pairwise comparisons: NC vs. HBA, NC vs. BA, NC vs. SC, SC vs. BA, SC vs. 
HBA, and BA vs. HBA. Univariate Receiver Operating Characteristic (ROC) analysis was 
implemented using Matlab (The MathWorks, Inc., Natick, MA) and was performed on 
each of the following measures: 1) nine skull volume measures, 2) nine skull distance 
measures, and 3) ten face distance measures; cranial circumference was included in each 
of the three data sets.  Area under the ROC curve (AUC) was reported.  The best overall 
classification accuracy for percent of all animals correctly classified on the ROC curve, 
its corresponding sensitivity for percent of cases correctly classified, and its corresponding 
specificity for percent of controls correctly classified, were also reported in each 
comparison. 
II.4 Results 
II.4.1 Maternal blood alcohol concentration 
The mean ± SEM maternal BACs at the end of alcohol infusion (1 hour; point in 
time at which BACs are known to peak) were significantly higher in the HBA treatment 
(280.0 ± 9.7 mg/dl) compared to the BA treatment (198.9 ± 8.6 mg/dl) (p = 0.001).   
II.4.2 Fetal and six-month-old body weights 
There were no significant differences between groups with regard to fetal birth 
weight (NC, 5.71 ± 0.35 kg; SC, 5.74 ± 0.33 kg; BA, 5.13 ± 0.49 kg; HBA, 4.68 ± 0.31 
kg) and six-month-old body weight (NC, 36.59 ± 4.33 kg; SC, 38.72 ± 4.04 kg; BA, 34.09 
± 2.25 kg; HBA, 33.02 ± 1.71 kg). 
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II.4.3 Correlations among measures 
As expected, Pearson correlations among all nine skull volume measures and the cranial 
circumference were strongly positive (Table II), and all were statistically significant (p < 
0.001).  The correlation coefficients ranged from r = 0.640, between the nasal and parietal 
bones, to r = 0.955 between total skull bone volume and frontal bone.  Each of the bone 
volumes were highly correlated with cranial circumference (r = 0.716 to 0.939). 
Pearson correlations among the nine skull distance measurements and cranial 
circumference were all positive (Table III), and 53% were statistically significant (p < 
0.001).  The significant correlations ranged from r = 0.530, between the interorbital 
distance and orbital height, to r = 0.897 between the bitragal width and cranial 
circumference.  Notably, all of the skull distance measures except orbital width and skull 
nasal length were significantly correlated with cranial circumference (r = 0.579 to 0.897). 
Orbital width did not correlate significantly with any of the other skull measures and skull 
nasal length significantly correlated with only one skull measure (lower facial depth).  
Pearson correlations among ten facial measurements and the cranial circumference 
were all positive and 43.6% were statistically significant (Table IV).  The significant 
correlation coefficients (p < 0.001) ranged from r = 0.460, between the outer canthal width 
and lower facial depth, to r = 0.977 between the nasal bridge length and facial nasal length.  
All of the facial distance measures except the lower facial height and palpebral fissure 
length were significantly correlated with the cranial circumference (r = 0.579 to 0.897). 
Orbital width did not correlate significantly with any of the other skull measures and skull 
nasal length significantly correlated with only one skull measure (lower facial depth).  
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Table II.  Pearson correlation coefficients among the nine volumetric skull measures and the cranial circumference 
measure   
 
 
 
 
 
 
 
 
 
 
 
 
All correlations are in bold, indicating correlations are significant at p < 0.001 for all measures
 Occipital Parietal Frontal Nasal Lacrimal Jugal Maxilla Mandible Total Skull 
Cranial 
Circ. 
Occipital 1.000 0.892 0.828 0.729 0.775 0.850 0.874 0.821 0.931 0.847 
Parietal 0.892 1.000 0.850 0.640 0.799 0.817 0.849 0.794 0.912 0.821 
Frontal 0.828 0.850 1.000 0.804 0.843 0.916 0.871 0.836 0.955 0.918 
Nasal 0.729 0.640 0.804 1.000 0.693 0.778 0.771 0.686 0.811 0.801 
Lacrimal 0.775 0.799 0.843 0.693 1.000 0.785 0.798 0.650 0.838 0.716 
Jugal 0.850 0.817 0.916 0.778 0.785 1.000 0.904 0.894 0.952 0.928 
Maxilla 0.874 0.849 0.871 0.771 0.798 0.904 1.000 0.839 0.950 0.882 
Mandible 0.821 0.794 0.836 0.686 0.650 0.894 0.839 1.000 0.915 0.869 
Total Skull 0.931 0.912 0.955 0.811 0.838 0.952 0.950 0.915 1.000 0.939 
Cranial 
Circ. 0.847 0.821 0.918 0.801 0.716 0.928 0.882 0.869 0.939 1.000 
 33 
 
Pearson correlations among ten facial measurements and the cranial circumference 
were all positive and 43.6% were statistically significant (Table IV).  The significant 
correlation coefficients (p < 0.001) ranged from r = 0.460, between the outer canthal width 
and lower facial depth, to r = 0.977 between the nasal bridge length and facial nasal length.  
All of the facial distance measures except the lower facial height and palpebral fissure 
length were significantly correlated with the cranial circumference (r = 0.543 to 0.837).  
Palpebral fissure length did not correlate significantly with any of the other facial 
measures.   
Pearson correlations between the ten facial distance measures and the nine 
underlying skull distance measures resulted in 29 positive correlations (p < 0.001) out of 
90 (32%, Table V).  A majority of these 29 reflected common structural features between 
facial landmarks and underlying skull structures (e.g., lower facial depth in the face 
correlated with the same measure in bone; inner and outer canthal widths in facial 
measures correlated with bone measures of minimal frontal width, bitragal width, bigonial 
width, and interorbital distance; facial nasal length correlated with bone lower facial depth, 
etc.).  Mid-facial depth (akin to the “flattened mid-face” of FAS) significantly correlated 
with six of the nine bone distance measures.  Palpebral fissure length and philtrum length 
are two facial measures most directly comparable to measures used in FAS 
dysmorphology evaluations.  Palpebral fissure length was not significantly correlated with 
any underlying bone measure and philtrum length was significantly correlated only with 
orbital height.  
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Table III.  Pearson correlation coefficients among the nine skull distance measures and the cranial circumference 
 Upper 
Facial 
Depth 
Lower 
Facial 
Depth 
Orbital 
Height 
Orbital 
Width 
Minimal 
Frontal 
Width 
Bitragal 
Width 
Bigonial 
Width 
Interorbital 
Distance 
Skull 
Nasal 
Length 
Cranial 
Circ. 
Upper Facial 
Depth 1.000 0.721 0.569 0.259 0.546 0.730 0.323 0.606 0.110 0.823 
Lower Facial 
Depth 0.721 1.000 0.665 0.256 0.468 0.677 0.513 0.569 0.595 0.812 
Orbital 
Height 0.569 0.665 1.000 0.469 0.217 0.531 0.583 0.530 0.433 0.605 
Orbital 
Width 0.259 0.256 0.469 1.000 0.374 0.496 0.246 0.402 0.046 0.462 
Minimal 
Frontal Width 0.546 0.468 0.217 0.374 1.000 0.681 0.429 0.581 0.157 0.754 
Bitragal 
Width 0.730 0.677 0.531 0.496 0.681 1.000 0.566 0.783 0.178 0.897 
Bigonial 
Width 0.323 0.513 0.583 0.246 0.429 0.566 1.000 0.623 0.414 0.579 
Interorbital 
Distance 0.606 0.569 0.530 0.402 0.581 0.783 0.623 1.000 0.286 0.780 
Skull Nasal 
Length 0.110 0.595 0.433 0.046 0.157 0.178 0.414 0.286 1.000 0.382 
Cranial Circ. 0.823 0.812 0.605 0.462 0.754 0.897 0.579 0.780 0.382 1.000 
Correlations in bold are significant at p < 0.001  
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Table IV.  Pearson correlation coefficients among the ten face distance measures and the cranial circumference 
 
Nasal 
Width 
Facial 
Nasal 
Length 
Nasal 
Bridge 
Length 
Philtrum 
Length 
Lower 
Facial 
Height 
Mid-
Facial 
Depth 
Lower 
Facial 
Depth 
Palpebral 
Fissure 
Length 
Inner 
Canthal 
Width 
Outer 
Canthal 
Width 
Cranial 
Circ. 
Nasal Width 1.000 0.631 0.576 0.634 0.517 0.717 0.502 0.318 0.606 0.463 0.728 
Facial Nasal 
Length 0.631 1.000 0.977 0.404 0.247 0.817 0.527 0.0583 0.488 0.259 0.582 
Nasal Bridge 
Length 0.576 0.977 1.000 0.396 0.197 0.767 0.497 -0.0136 0.490 0.251 0.544 
Philtrum 
Length 0.634 0.404 0.396 1.000 0.624 0.506 0.337 0.241 0.554 0.547 0.543 
Lower Facial 
Height 0.517 0.247 0.197 0.624 1.000 0.413 0.0809 0.325 0.378 0.364 0.382 
Mid-Facial 
Depth 0.717 0.817 0.767 0.506 0.413 1.000 0.758 0.199 0.643 0.463 0.822 
Lower Facial 
Depth 0.502 0.527 0.497 0.337 0.0809 0.758 1.000 0.141 0.579 0.460 0.754 
Palpebral 
Fissure Length 0.318 0.0583 -0.0136 0.241 0.325 0.199 0.141 1.000 0.144 0.288 0.222 
Inner Canthal 
Width 0.606 0.488 0.490 0.554 0.378 0.643 0.579 0.144 1.000 0.836 0.837 
Outer Canthal 
Width 0.463 0.259 0.251 0.547 0.364 0.463 0.460 0.288 0.836 1.000 0.724 
Cranial Circ. 0.728 0.582 0.544 0.543 0.382 0.822 0.754 0.222 0.837 0.724 1.000 
Correlations in bold are significant at p < 0.001
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Table V.  Pearson correlation coefficients among the ten face distance measures and the nine skull distance measures 
 Nasal 
Width 
Face 
Nasal 
Length 
Nasal 
Bridge 
Length 
Philtrum 
Length 
Lower 
Facial 
Height 
Mid-
Facial 
Depth 
Lower 
Facial 
Depth 
Palpebral 
Fissure 
Length 
Inner 
Canthal 
Width 
Outer 
Canthal 
Width 
Upper Facial 
Depth 0.534 0.320 0.311 0.523 0.357 0.745 0.668 0.213 0.660 0.556 
Lower Facial 
Depth 0.674 0.760 0.697 0.505 0.288 0.952 0.812 0.117 0.617 0.510 
Orbital Height 0.507 0.467 0.483 0.537 0.293 0.494 0.385 0.380 0.512 0.446 
Orbital Width 0.314 0.062 0.078 0.377 0.197 0.322 0.484 0.465 0.483 0.517 
Minimal 
Frontal Width 0.295 0.288 0.274 0.305 0.210 0.532 0.523 -0.013 0.705 0.673 
Bitragal Width 0.605 0.379 0.317 0.478 0.330 0.687 0.594 0.191 0.761 0.753 
Bigonial 
Width 0.494 0.495 0.488 0.445 0.244 0.482 0.240 0.075 0.675 0.691 
Interorbital 
Distance 0.533 0.418 0.430 0.409 0.143 0.588 0.507 0.059 0.813 0.694 
Skull Nasal 
Length 0.467 0.919 0.920 0.322 0.247 0.808 0.437 0.071 0.349 0.126 
Correlations in bold are significant at p < 0.001
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Figure IV.  Treatment effects on nine volumetric skull measures and the cranial 
circumference measures.  The y axis indicates the mean volume (+ SEM) in mm3 for 
the eight segmented bone volumes and total skull volume, or length (in mm) for 
cranial circumference.  Note the scale for the six bones in the top panels (maximum 
of 100,000 mm3) differs from that in the lower panels for the lacrimal and jugal bones 
(maximum of 20,000 mm3).  For the bone volumes, the ANOVA α level was adjusted 
to 0.0056 (=0.05/9) for the nine ANOVAs performed, followed by the Holm-Sidak 
method for pairwise comparisons (p < 0.05).  For cranial circumference, the ANOVA 
α level was 0.05 followed by the Holm-Sidak method for pairwise comparisons (p < 
0.05).  Significant group differences are indicated within each panel.  An asterisk (*) 
indicates that the volumes of two control groups (NC and SC) were significantly 
greater than the two alcohol-exposed groups (BA and HBA); NC and SC did not 
differ from each other, and BA and HBA did not differ from each other.   
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II.4.4 Skull bone volumes and cranial circumference 
As shown in Figure IV, significant effects of prenatal treatment were evident in 
eight of the nine volumetric skull measures (Bonferroni-corrected α = 0.0056) and in the 
cranial circumference measure (p < 0.05).  Bones with significant treatment effects 
included the mandible (F (3, 35) = 15.988, p < 0.001), frontal (F (3, 35) = 24.906, p < 
0.001), parietal (F (3, 35) = 26.724, p < 0.001), occipital (F (3, 35) = 18.285, p < 0.001), 
maxilla (F (3, 35) = 12.850, p < 0.001), lacrimal (F (3, 35) = 16.894, p < 0.001), jugal (F 
(3, 35) = 14.740, p < 0.001), total skull bone volume (F (3, 35) = 23.944, p < 0.001), and 
cranial circumference (F (3, 35) = 15.089, p < 0.001).  Pairwise group comparisons (Holm-
Sidak p < 0.05) confirmed that the bone volumes of the HBA and BA groups were 
significantly reduced relative to the NC and SC groups for all skull bones except the nasal 
bone, the total skull bone volume, and the cranial circumference.  There were no 
significant differences between the BA and HBA groups, or between the NC and the SC 
groups.    
Covariance analyses using either total skull bone volume or cranial circumference 
and sex as covariates were used to assess alcohol treatment effects on individual skull 
bone volumes.  This was done to determine if the individual bone volumes would remain 
significant after the effects of head size or total skull bone volume and sex differences 
were removed.  After covarying for total skull bone volume and sex, treatment effects on 
volumetric skull measures were no longer significant (Bonferroni-corrected α = 0.00625).  
This was consistent with the strong correlations between total skull bone volume and the 
volume of each individual bone.  After covarying for cranial circumference and sex, 
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significant effects among the four treatment groups were found in four of the nine 
volumetric skull measures (Bonferroni-corrected α = 0.0056; Figure V).  These included 
the frontal, parietal, and occipital bones, as well as the total skull bone volumes.  Pairwise 
comparisons (Holm-Sidak p < 0.05) showed the HBA treatment differed from both NC 
and SC groups for the parietal and occipital bones.  The occipital bone was the only bone 
volume measure to show a significantly greater reduction in the HBA treatment compared 
to the BA treatment, suggesting a dose-dependent effect.  Thus, when variance associated 
with cranial circumference (and sex) was statistically controlled, the parietal and occipital 
bones still distinguished the HBA group from the NC and SC groups. 
II.4.5 Craniofacial distance measures 
Significant treatment effects were evident in five of the nine skull distance 
measures (Bonferroni-corrected α = 0.0056; Figure VI), including the upper facial depth 
(F (3, 35) = 8.997, p < 0.001), bitragal width (F (3, 35) = 10.949, p < 0.001), interorbital 
distance (F (3, 35) = 7.806, p < 0.001), and nasal length (F (3, 35) = 5.575, p < 0.001).  
Holm-Sidak pairwise group comparisons showed significant differences (p < 0.05) 
between the BA and HBA groups and the NC and SC groups for upper facial depth, 
bitragal width, and interorbital distance.  No significant differences were found between 
the BA and HBA groups, or between the NC and SC groups in these three skull distance 
measures.  Bigonial width showed differences between the HBA and SC groups, but HBA 
did not differ significantly from NC.  Nasal length showed differences between the BA 
and HBA groups, but neither of those was significantly different from either the NC or SC 
groups.  
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Figure V.  Treatment effects on nine volumetric skull measures while controlling for 
cranial circumference and sex, showing the adjusted group means (+ SEM) after 
removal of the influence of the two covariates.  The y axis indicates the adjusted 
volume in mm3 for the nine measures (note scale differences between the top and 
bottom panels).  For bone volumes, the ANOVA α level was adjusted to 0.0056 
(=0.05/9) for the nine ANOVAs performed, followed by the Holm-Sidak method for 
pairwise comparisons (p < 0.05).  For cranial circumference, the ANOVA α level was 
0.05 followed by the Holm-Sidak method for pairwise comparisons (p < 0.05).  
Significant group differences are indicated within each panel.  Note that after 
controlling for effects of differences in cranial circumference, the effects of the heavy 
binge alcohol (HBA) treatment relative to controls were still detectable in the parietal 
and occipital bone volumes, and the HBA even differed from the BA group in the 
occipital bone volume.  Significance between NC vs SC is indicated with a dagger 
sign (†), BA vs SC is indicated with a delta sign (Δ), HBA vs SC is indicated with a 
pound sign (#), HBA vs NC is indicated with a plus sign (+), and HBA vs BA is 
indicated with a double dagger sign (‡). 
  
 41 
 
For the facial distance measures, significant treatment effects were found in five 
of the ten measures (Bonferroni-corrected α = 0.005; Figure VII), including the philtrum 
length (F (3, 35) = 5.244, p < 0.001), mid-facial depth (F (3, 35) = 6.946, p < 0.001), lower 
facial depth (F (3, 35) = 5.195, p < 0.001), inner canthal width (F (3, 35) = 15.097, p < 
0.001), and outer canthal width (F (3, 35) = 6.618, p < 0.001).  However, follow-up Holm-
Sidak pairwise group comparisons for these five measures indicated that only the inner 
canthal width showed significant reductions (p < 0.05) in both alcohol-exposed groups 
compared to the two control groups.  None of the other measures showed significant 
differences between the alcohol-exposed and both control groups.  Covariance analyses 
were performed to evaluate the effects of cranial circumference and sex on the nine skull 
distance measures (Bonferroni-corrected α = 0.0056) and the ten face distance measures 
(Bonferroni-corrected α = 0.005).  None of the skull or face measures remained significant 
between the alcohol-exposed groups and the control groups.   
II.4.6 Discriminant analysis 
Area under ROC curve (AUC) results from the univariate ROC analyses are shown 
in Table VI, VII, and VIII.  Several bone volumetric measures were identified as best 
predictors in classifying between alcohol-exposed groups and control groups across the 
ROC analysis of the six treatment pairs (Table VI).  The mandible, frontal bone, parietal 
bone, and total skull bone volumes achieved an AUC of 0.99-1.0, with the best overall 
accuracy of 100% (sensitivity 100%, specificity 100%).  The occipital bone provided the 
best discrimination between the BA and HBA groups (AUC = 0.708; accuracy of 75%, 
sensitivity and specificity of 75%).  For the skull distance measures (Table VII), the 
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Figure VI.  Treatment effects on nine skull distance measures.  The y axis indicates 
the mean length (+ SEM) in mm.  The ANOVA α level was adjusted to 0.0056 
(=0.05/9) for the nine ANOVAs performed, followed by the Holm-Sidak method for 
pairwise comparisons (p < 0.05).  Significant group differences are indicated within 
each panel. An asterisk (*) indicates significance between the following four pairs:  
BA vs NC; HBA vs NC; BA vs SC; and HBA vs SC.  Significance between HBA vs 
SC is indicated with a pound sign (#) and significance between HBA vs BA is 
indicated with a double dagger sign (‡).  
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Figure VII.  Treatment effects on ten face measures.  The y axis indicates the mean 
length (+ SEM) in mm.  The ANOVA α level was adjusted to 0.005 (=0.05/10) for the 
ten ANOVAs performed, followed by the Holm-Sidak method for pairwise 
comparisons (p < 0.05).  Significant group differences are indicated within each 
panel.  An asterisk (*) indicates significance between the following four pairs:  BA vs 
NC; HBA vs NC; BA vs SC; and HBA vs SC.  Significance between BA vs SC is 
indicated with delta sign (Δ), HBA vs SC is indicated with a pound sign (#), and HBA 
vs NC is indicated with a plus sign (+).  
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 interorbital distance was the best predictor in distinguishing between an alcohol and 
control treatment (AUC between 0.984-1.0) with overall accuracies between 93.8-100% 
(sensitivities between 87.5-100%, specificities of 100%).  For the facial soft-tissue 
measures (Table VIII), the inner canthal width was the best predictor in distinguishing 
between an alcohol and control treatment.  The AUC ranged between 0.906-1.0, and 
accuracies between 90-100% (sensitivities 87.5-100%, specificities 75-100%).  The 
cranial circumference was the next best predictor in distinguishing between an alcohol and 
control treatment, with AUC ranging between 0.875-0.984, and accuracies between 93.8-
95% (sensitivities 87.5-100%, specificities 87.5-100%).  Of the skull and facial distance 
measures, the best predictors to classify between the BA and HBA groups were the skull 
nasal length (AUC 0.802; overall accuracy of 75%; sensitivity 58.3% and specificity 
100%) and nasal bridge length (AUC 0.781; overall accuracy of 75%; sensitivity 83.3% 
and specificity 62.5%).  
II.4.7 Relative sensitivity of total skull bone volume and cranial circumference 
From the discriminant analysis (above and Table VI), total skull bone volume was 
100% accurate in classifying alcohol-exposed and control lambs, more accurate than the 
cranial circumference (with which it was highly correlated, r = 0.939).  The effect size of 
the alcohol treatment for total skull bone volume (Cohen’s d = 2.81) was larger than the 
effect size for cranial circumference (Cohen’s d = 2.23).  In the context of potential 
usefulness of total skull bone volume as a screening measure to help identify a larger 
proportion of individuals with FASD, the relative sensitivity of total skull bone volume (a 
novel candidate measure) was compared to the cranial circumference (similar to head 
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Table VI.  Results of univariate ROC analysis: Areas under ROC curve (AUCs) are shown for (a) skull bone volumetric 
measurements and cranial circumference 
 No Covariates 
(a) Bone BA vs NC HBA vs NC BA vs SC HBA vs SC NC vs SC HBA vs BA 
Mandible 1 1 1 1 0.734 0.656 
Frontal 1 1 1 1 0.594 0.615 
Parietal 1 0.990 1 1 0.766 0.625 
Occipital 0.984 1 0.938 0.979 0.547 0.708 
Nasal 0.891 0.771 0.828 0.740 0.531 0.510 
Maxilla 1 0.958 0.969 0.927 0.563 0.563 
Lacrimal 0.953 0.927 0.984 0.958 0.734 0.542 
Jugal 0.984 0.979 1 1 0.547 0.635 
Total skull bone   1 1 1 1 0.578 0.531 
Cranial circumference 0.984 0.948 0.984 0.875 0.531 0.635 
Best AUC results in each comparison are highlighted in bold.
 46 
 
Table VII.  Results of univariate ROC analysis: Areas under ROC curve (AUCs) are shown (b) skull distance 
measurements 
(b) Skull BA vs NC HBA vs NC BA vs SC HBA vs SC NC vs SC HBA vs BA 
Upper facial depth 0.906 0.885 0.922 0.844 0.500 0.698 
Lower facial depth 0.719 0.813 0.703 0.771 0.547 0.583 
Cranial circumference 0.969 0.927 0.875 0.833 0.578 0.542 
Orbital height 0.547 0.542 0.844 0.781 0.844 0.542 
Orbital width 0.734 0.698 0.781 0.792 0.578 0.646 
Minimal frontal width 0.953 0.927 0.734 0.760 0.500 0.510 
Bitragal width 
 
0.891 0.865 0.906 0.844 0.531 0.656 
Bigonial width 0.578 0.510 0.844 0.823 0.797 0.604 
Interorbital distance 0.984 0.990 1 1 0.781 0.500 
Skull Nasal length 0.625 0.750 0.625 0.677 0.547 0.802 
Best AUC results in each comparison are highlighted in bold.
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Table VIII.  Results of univariate ROC analysis: Areas under ROC curve (AUCs) are shown for (c) face distance 
measurements and cranial circumference 
(c) Face BA vs NC HBA vs NC BA vs SC HBA vs SC NC vs SC HBA vs BA 
Nasal width 0.891 0.781 0.828 0.708 0.609 0.594 
Face Nasal length 0.531 0.771 0.531 0.719 0.578 0.729 
Nasal bridge length 0.531 0.802 0.500 0.719 0.516 0.781 
Philtrum length 0.766 0.563 0.938 0.833 0.766 0.677 
Lower facial height 0.688 0.510 0.875 0.563 0.719 0.688 
Mid-facial depth 0.766 0.854 0.703 0.760 0.563 0.583 
Lower facial depth 0.781 0.917 0.672 0.729 0.734 0.552 
Palpebral fissure length 0.641 0.510 0.750 0.531 0.516 0.729 
Inner canthal width 1 0.906 0.984 0.906 0.688 0.573 
Outer canthal width 0.906 0.646 0.891 0.802 0.688 0.677 
Cranial circumference 0.948 0.948 0.984 0.875 0.531 0.635 
Best AUC results in each comparison are highlighted in bold.
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circumference in clinical screening in which scores < 10th percentile are used to help 
diagnose FAS).  Lambs of the NC and SC groups were combined (n = 16) and the 10th 
percentile of this combined control group was established for both the cranial 
circumference measure (390.7 mm) and the total skull bone volume measure (254358 
mm3).  Alcohol-exposed lambs of both groups (BA and HBA) were then predicted based 
on whether or not they were less than the 10th percentile cutoff.  For cranial circumference, 
14 out of 20 alcohol-exposed lambs (70%) were under the cutoff (7/8 BA; 1/12 HBA), 
whereas all 20 of the alcohol-exposed lambs (100%) were under the cutoff for total skull 
volume.  A two-tailed Fisher’s Exact Test confirmed that the classification based on total 
skull bone volume was significantly more sensitive than the one based on cranial 
circumference (p = 0.020).  
 II.5 Discussion 
Although facial dysmorphology is a cardinal feature of FAS, children with FASD 
may not have identifiable features or their facial features may be too subtle to detect 
reliably on clinical exam [99, 130, 131].  As a result, many children exposed prenatally to 
alcohol are not recognized as having FASD until later in adolescence when unruly 
behavior or developmental and learning disabilities become problematic.  This study of 
lambs born to ewes given alcohol during the first trimester equivalent tested whether more 
sensitive structural indices could be achieved from a single CT scan of the head.  
Quantitative measures obtained from this scan provide a novel biomarker for prenatal 
alcohol exposure utilizing individual bone volumes and collectively, the total skull bone 
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volume.  The scan also allows for morphometric measures, skull bone and soft tissue, 
which model anthropometric studies in humans [103, 132, 133] and rodents [122, 126]. 
An important discovery from this sheep model is that quantitative volume 
measures of the bones of the neurocranium may be one of the most sensitive structural 
indicators of the effects of binge alcohol during the first eight weeks of human pregnancy.  
Both the binge alcohol (BA) and heavy binge alcohol (HBA) treatments resulted in 
significant and severe reductions in total skull bone volume, volumes of the frontal, 
parietal, occipital, maxilla, mandible, lacrimal, and jugal bones, as well as cranial 
circumference.  After statistically controlling for smaller cranial circumference in the 
alcohol-exposed groups, significant reductions in the volumes of the parietal and occipital 
bones were evident in the HBA group.  Discriminant analysis showed that the frontal bone, 
parietal bone and total skull bone volumes achieved 100% sensitivity and specificity in 
predicting prenatal treatment (alcohol or control).  Volumes of these bones were better 
predictors of alcohol exposure than cranial circumference, and were consistent with the 
greater effect size of alcohol treatment for total skull bone volume (d = 2.81) and cranial 
circumference (d = 2.23).  All alcohol-exposed lambs were at or below the 10th percentile 
of the control lamb distribution for total skull bone volume.  The sensitivity of 
classification of alcohol-exposure based on this 10th percentile cutoff for total skull 
volume was significantly better than a similar classification based on a 10th percentile 
cutoff for cranial circumference.  Taken together, these findings suggest that CT derived 
measures of neurocranial bone volumes may provide a novel method for identifying 
children with FASD.  
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Cranial circumference in this model is directly parallel to reduced head 
circumference in FAS.  Head circumference is routinely evaluated on a physical exam 
[103, 134] and is a simple, direct and easily-obtained measure that has population norms.  
The smaller head circumference found in children with FAS [135, 136] has been modeled 
in mice exposed to alcohol prenatally [126] and was replicated in this study.  However, 
the results in this study indicate that total skull volume is more sensitive and more accurate 
than cranial circumference in predicting prenatal alcohol exposure, even though the two 
measures were strongly correlated (r = 0.939).  These findings suggest that, if skull bone 
volume determinations could safely become available in alcohol-exposed and non-
exposed children, the neurocranium bone volume would be a more accurate predictor of 
prenatal alcohol exposure than either facial dysmorphology or head circumference.  
Although CT scanning of the head is not without risk and segmentation of the skull 
bones may be clinically demanding, quantitative CT scans eventually could provide better 
identification of prenatal alcohol exposure in clinical screening of children at risk for 
FASD.  The lack of age-specific norms for cranial bone volumes and the potential risk of 
unnecessary radiation exposure with elective use of CT in children currently limits 
application of this approach in helping identify children with FASD.  While it may be 
possible to build a reasonably large normative data base from CT scans in children 
undergoing head CT for medical purposes, perhaps it is more difficult to justify non-
diagnostic CT scans for FASD (or other) children.  Nevertheless, research and 
development efforts in biomedical imaging are improving safety by lowering scan times 
and creating new technology that reduces radiation exposure.  For example, electron-beam 
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CT is a relatively new technology.  A study in children found that multi-detector CT 
delivered higher doses of radiation compared with the doses delivered in electron-beam 
CT [137].  In time, as electron-beam CT and other technology becomes more clinically 
available, it is reasonable to expect that the safety of CT will sufficiently outweigh the 
risks and that the quantitative approaches used in this study will become clinically feasible 
on a routine basis. 
Prenatal alcohol exposure significantly affected all three of the neurocranium 
bones (frontal, parietal and occipital) and four of the five viscerocranium bones (maxilla, 
mandible, lacrimal, jugal, but not nasal).  Overall, the bone volume changes were highly 
correlated, such that in the analysis using total skull bone volume as a covariate, none of 
the individual bone volumes remained significant.  However, the neurocranium bone 
volumes were generally better predictors of prenatal alcohol exposure in the discriminant 
analysis, and only the parietal and occipital bones distinguished the HBA group after the 
effects of cranial circumference were statistically removed.  The neurocranium bones are 
directly and anatomically related to the three skull distance measures (upper facial depth, 
bitragal width, interorbital distance) and one facial measure (inner canthal width) that were 
significantly reduced in the binge and heavy binge alcohol treatments.  Thus, it appears 
that prenatal binge alcohol exposure effects on head and skull measures may be more 
directly related to growth of the neurocranium than the viscerocranium, and relative to 
routine FAS screening measures, alcohol-induced reductions in the neurocranium 
volumes may provide better detection of prenatal alcohol exposure.   
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In comparing the two binge alcohol exposure treatments, no significant differences 
were evident in any of the volumetric or linear distances in the BA and HBA treatments 
in the absence of covariance analysis.  The two alcohol treatments used in this “weekend 
binge drinking” model of the first eight weeks of human pregnancy both produced 
relatively high peak blood alcohol concentrations (199 and 280 mg/dl, respectively).  Both 
alcohol treatments were equally prone to produce skull volume and craniofacial changes.  
The 1.75 g/kg per day dose was sufficient to induce craniofacial abnormalities.  The only 
differences identified in the BA and HBA treatments were from the covariance analysis 
(with cranial circumference and sex as covariates), which statistically controlled for 
overall effects of head size.  In that analysis, the HBA treatment produced significantly 
greater reductions than the BA treatment in the adjusted means of the occipital bone 
volume.  The occipital bone was also the most accurate predictor in distinguishing between 
the BA and HBA treatments in the discriminant analysis.  This suggests that the occipital 
bone volume may be a sensitive biomarker for increasing severity of binge drinking during 
the first trimester. 
In terms of craniofacial distance measures, reductions in three of the nine bone 
distances (upper facial depth, bitragal width, interorbital distance) and one of the ten soft-
tissue face distances (inner canthal width) distinguished BA and HBA lambs from NC and 
SC lambs.  All four measures were highly correlated with cranial circumference.  When 
cranial circumference was used as a covariate, none of the measures remained significant 
between the BA and HBA groups and the NC and SC groups.  The interorbital distance 
predicted the alcohol-exposed treatments from the control treatments with 93.8-100% 
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accuracy (87.5-100% sensitivities and 93.8-100% specificities) and, the inner canthal 
width was 90-100% accurate (87.5-100% sensitivities and 75-100% specificities).  There 
were significant correlations between several facial measures and the underlying bone 
measures that were closely associated with those facial features.  Significant reductions in 
the correlated measures of interorbital distance (bone) and inner canthal width (face), as 
well as the high accuracy in classifying prenatal alcohol treatment based on interorbital 
distance and on inner canthal width, suggests that these two measures (associated with 
reduced distances between the eyes) may also help identify children with FASD.  These 
findings are the first report of quantitative skull and facial morphometric changes in the 
sheep model of maternal binge alcohol exposure during a portion of the first trimester 
equivalent.      
A previous rodent study analyzed facial measurements on embryonic day 17 
C57BL/6N mice and found significant treatment effects in 12 of the 15 measures analyzed.  
Four measures (upper face, mid-face, nasal length, nasal bridge) identified the alcohol 
group from the pair and chow fed groups [122], which showed only partial correspondence 
to the four measures identified in this sheep study (upper facial depth, bitragal width, 
interorbital distance, and inner canthal width).  Differences between the mouse model and 
sheep model outcomes could be explained either by differences in 1) alcohol exposure 
models (with the sheep model involving a more direct experimental control over binge-
like exposure), 2) the older developmental status of the sheep (peripubertal lambs 
compared to late-fetal mice), or 3) species differences between sheep and rodents in how 
alcohol alters craniofacial development.    
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A comparable CT study of skull morphology was conducted in 21-day-old 
C57BL/6J mice that showed bone volumes were capable of identifying alcohol-exposed 
offspring [126], similar to findings in this study.  The mouse model studies, involving 
maternal consumption of alcohol liquid diets, produce prenatal and postnatal growth 
deficits in offspring that can be conflated with craniofacial bone growth deficits.  In this 
sheep model paradigm, there were no significant effects on birth weight or postnatal 
growth of the lambs.   
Palpebral fissure length is a cardinal feature to assess FAS in children [97, 98, 133, 
138], yet palpebral fissure length was not reliably affected in this sheep model of prenatal 
alcohol exposure and it was not significantly correlated with cranial circumference or total 
skull bone volume.  The results of this study indicate that neither the orbital height, orbital 
width (bone) nor the palpebral fissure length (face) were significantly different between 
alcohol-exposed and control lambs.  This contrasts with a human study in which 
significant reductions were found in palpebral fissure length, inner canthal width and outer 
canthal width [132].  A recent human study concluded that palpebral fissure length and 
head circumference are independent of each other and that short palpebral fissures are 
likely reduced due to forebrain damage, not necessarily due to smaller head size [129].  In 
the embryonic mouse model, a direct correlation was identified between reduced palpebral 
fissure length and reduced globe size as well as forebrain reduction implicating a 
correlation to forebrain damage [139].  Palpebral fissure length in this sheep model was 
not useful in distinguishing between the four treatment groups.  In contrast and consistent 
with the human study by Moore and colleagues, the sheep model did find significant 
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alcohol-induced reductions in the inner canthal width relative to controls (NC; SC), and 
the outer canthal width was significantly reduced relative to the SC group.  This suggests 
that in the sheep model, craniofacial effects are more prominent in measures linked to 
craniofacial and skull width development (inner and outer canthal widths, interorbital 
widths, bitragal width, upper facial depth) rather than direct orbital measures.  These 
differences may reflect species differences in response to alcohol exposure, or they may 
point to a previously unrecognized sensitivity of mid-facial width measurements in FASD 
screening.  The Moore et al. study also included a wide range of ages, an ethnically diverse 
population and unknown maternal drinking history.  These sources of variance may have 
important influences on craniofacial morphometry.   
There are many translational advantages of the sheep model of FASD (Cudd, 
2005), in which dose, pattern and timing of alcohol exposure are experimentally 
controlled.  The resulting blood alcohol concentrations are known and these underscore 
the translational importance of the current findings that identify neurocranium bone 
volumes as a potential biomarker of prenatal alcohol exposure.  Sheep model studies are 
limited by several factors that make it difficult to get large sample sizes and adequate sex 
representation for experiments.  Studies take longer to complete, are more labor intensive 
and are more expensive than rodent studies.  Despite these limitations, experimental 
studies can be done utilizing the sheep model in a translational role for preclinical studies 
of FASD.  This is due to improved ability in controlling and matching the experimental 
conditions of daily patterns, developmental timing of alcohol exposure more similar to 
humans and the development of measures to advance diagnostic phenotypes of FASD.  
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Sheep have body weights and head/brain sizes that are more comparable to humans and 
they have long gestational periods (147 days) closely resembling human gestation (280 
days).  Sheep also have brain development stages in utero that can be matched more 
directly to prenatal brain development in humans [57].  Findings in this study illustrate the 
translational value of the sheep model, confirming that the effects on bone volumes are 
replicable in multiple species, but also provide novel evidence that neurocranium bone 
volumes may provide an optimal structural biomarker of the effects of first trimester binge 
drinking associated with FASD. 
To summarize, these results confirmed our hypothesis that CT morphometric 
analysis is an effective tool for detecting prenatal binge alcohol exposure in lambs.  Lambs 
born to ewes exposed to alcohol during the period of embryonic development comparable 
to the first eight weeks of human pregnancy had reduced CT-derived volumetrics of the 
bones and, less reliably, reduced facial and skull measures.  Discriminant analysis of CT 
measures could identify alcohol-exposed from non-exposed lambs with 100% accuracy.  
These changes correlate to reduced craniofacial bone volumes in the rodent model and 
reduced head circumference in both rodents and humans.  Facial measurements in the 
sheep share some similarities in humans with FAS, including reductions in the upper facial 
depth, bitragal width, and inner canthal distance, but other dysmorphic effects seen in 
humans were not reliably produced in this sheep model (palpebral fissure width). 
Several findings in this study highlight the potential translational value of the sheep 
model and the development of better diagnostic tools for craniofacial phenotypes of 
FASD.  To the extent that CT scans can become feasible in FASD research settings, the 
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findings in this study predict several relatively straightforward measures that should 
accurately identify otherwise non-dysmorphic children who experienced binge-like 
alcohol exposure during the first trimester.  The best predictors would most likely be 
segmented bone volumes of the neurocranium (frontal, parietal, occipital or volume of the 
total skull).  These measures should have high sensitivity and specificity in classifying 
prenatal binge-alcohol exposed children from non-exposed children.  Inclusion of the 
occipital bone volume may also help determine which children were heavily exposed 
during the first trimester (likely to include those diagnosed with FAS).  Concurrent use of 
multiple quantitative CT measures (e.g., neurocranium bone volumes together with cranial 
circumference, interorbital distance and inner canthal width) may further improve the 
reliability of classification.  Implementation of CT morphometrics would also require 
establishment of age-specific normative data.  The degree to which these bone structural 
phenotypes (observed in this study in peripubertal sheep) might change over development 
is not known, and whether they could be applied to earlier ages (childhood) or later ages 
(adolescence or young adulthood) remains to be determined.  The implication is that 
development of comparative CT analysis may significantly improve the identification of 
children with FASD; individuals whose status otherwise would either be unknown, 
uncertain or overlooked.   
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CHAPTER III  
MATERNAL CHOLINE SUPPLEMENTATION IN A SHEEP MODEL OF 
FIRST TRIMESTER BINGE ALCOHOL FAILS TO PROTECT AGAINST 
BRAIN VOLUME REDUCTIONS IN PERIPUBERTAL LAMBS*  
 
III.1 Overview 
Fetal alcohol spectrum disorder (FASD) is a leading potentially preventable birth 
defect.   Poor nutrition may contribute to adverse developmental outcomes of prenatal 
alcohol exposure and supplementation of essential micronutrients such as choline have 
shown benefit in rodent models.  The sheep model of first trimester binge alcohol exposure 
was used in this study to model the dose of maternal choline supplementation used in an 
ongoing prospective clinical trial involving pregnancies at risk for FASD.  Primary 
outcome measures included volumetrics of the whole brain, cerebellum and pituitary 
derived from magnetic resonance imaging 
 (MRI) in six-month-old lambs, testing the hypothesis that alcohol-exposed lambs 
would have brain volume reductions that would be ameliorated by maternal choline 
supplementation.  Pregnant sheep were randomly assigned to one of five groups - heavy 
binge alcohol (HBA; 2.5 g/kg/treatment ethanol), heavy binge alcohol plus choline 
supplementation (HBC; 2.5 g/kg/treatment ethanol and 10 mg/kg/day choline), saline 
control (SC), saline control plus choline supplementation (SCC; 10 mg/kg/day choline and   
 
 
 
*Reprinted with permission from “Maternal choline supplementation in a sheep model of first trimester binge alcohol fails to protect 
against brain volume reductions in peripubertal lambs” by Birch SM, Lenox MW, Kornegay JN, Paniagua B, Styner MA, Goodlett 
CR, Cudd TA, Washburn SE, 2016.  Alcohol, 55: 1-8, Copyright © 2016 by Elsevier Inc.    
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normal control (NC).  Ewes were given intravenous alcohol (HBA, HBC; mean peak 
BACs of ~280 mg/dl) or saline (SC, SCC) on three consecutive days per week from 
gestation day (GD) 4-41; choline was administered on GD 4-148.  MRI scans of lamb 
brains were performed postnatally on day 182.  Lambs from both alcohol groups (with or 
without choline) showed significant reductions in total brain volume; cerebellar and 
pituitary volumes were not significantly affected.  This is the first report of MRI-derived 
volumetric brain reductions in a sheep model of FASD following binge-like alcohol 
exposure during the first trimester.  These results also indicate that maternal choline 
supplementation comparable to doses in human studies fails to prevent brain volume 
reductions typically induced by first trimester binge alcohol exposure.  Future analyses 
will assess behavioral outcomes along with regional brain and neurohistological measures.  
III.2 Introduction 
Prenatal alcohol exposure results in multiple teratogenic effects on central nervous 
system (CNS) development, including altered cellular proliferation and migration, 
decreased synaptic connectivity, increased apoptotic cell death and impaired myelination.  
These may all contribute to brain growth restriction, neurodevelopmental delays, changes 
in structure and function and resultant abnormal behavior and cognition [140-144].   The 
presence of CNS abnormalities, together with dysmorphic facial features and growth 
deficits, constitute the three characteristic phenotypes required to diagnose fetal alcohol 
syndrome (FAS) [98, 99].  However, the majority of children expressing adverse cognitive 
and neurodevelopmental effects resulting from prenatal alcohol exposure do not meet the 
diagnostic criteria for FAS.  An umbrella classification, fetal alcohol spectrum disorders 
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(FASD), has been adopted to encompass the full spectrum of alcohol-related 
neurodevelopmental disorders [18, 145, 146].   
Given that FASD is a leading potentially preventable birth defect [20], with 
prevalence estimates ranging from 1% [103, 104] to as high as 2-5% [105], priorities have 
been placed on efforts to develop early interventions that may provide significant benefits 
and thus mitigate the lifelong effects of FASD.  Choline supplementation has emerged as 
a particularly promising nutraceutical therapeutic approach, based mainly on positive 
results from preclinical rodent models [147].  
Choline is classified as an essential nutrient that has many important roles in brain 
development and function.  It is involved directly as a precursor or through metabolites in 
maintaining the integrity of cell membranes and cell signaling, lipid and cholesterol 
transport, synthesis of the neurotransmitter acetylcholine, methyl metabolism, and DNA 
methylation [148, 149].  The recommended daily intake of choline for pregnant women is 
450 mg/day [150].  During pregnancy, phosphatidylcholine production is increased in the 
liver, providing an important source of choline to the developing fetus [151].  Choline 
deficiency has been implicated in the molecular etiology of FASD because alcohol can 
decrease choline availability to the fetus by several mechanisms.  The detrimental effects 
of choline deficiency may be further exacerbated by reduced maternal intake of choline 
and thus fetal deficiency of choline can ultimately contribute to abnormal brain 
development [151, 152].   
Studies with rodent models of FASD over the last 15 years by Thomas and 
colleagues as well as by others have demonstrated that choline administration during 
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and/or after the time of alcohol exposure (either during gestation or during the early 
neonatal period of brain development in rats comparable to that of the human third 
trimester) can significantly improve a variety of alcohol-induced neurobehavioral deficits.  
Choline supplementation has been shown to improve deficits in behavioral and physical 
development and brain weight [153], spatial learning and memory [154, 155], spatial 
working memory [156], visual discrimination [157], locomotor hyperactivity [158, 159], 
trace fear conditioning [160], and trace eyeblink conditioning [161].  Positive 
improvements associated with choline supplementation in the rodent models were 
achieved with daily doses (typically 250 mg/kg/day) that far exceed the minimum daily 
choline requirements for rodents.   
Based on these promising results from the rodent models, the Collaborative 
Initiative on Fetal Alcohol Spectrum Disorders (CIFASD) designed and implemented a 
prospective randomized clinical trial in the Ukraine involving multivitamin and mineral 
(MVM) supplements in which a subgroup of the MVM group was also given a choline 
supplement (750 mg/day, about 10 mg/kg/day) as an additional component of the MVM 
intervention.  The sheep model study reported here was concurrently designed to optimize 
the translational comparisons with the prospective randomized human clinical trial.  A 
choline dosing regimen of 10 mg/kg/day was selected and the choline supplement was 
started at the beginning of pregnancy (at the start of the binge alcohol exposure period), 
whereas in clinical trials, participants were enrolled after the first prenatal appointment 
(typically around 19 weeks gestation).  Choline supplementation was initiated at the start 
of alcohol exposure in the current study to maximize the likelihood of benefits from early 
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intervention.  This is the first report of the sheep model with choline supplementation 
which models the CIFASD Ukrainian clinical trial which was recently published [162].   
Although rodent studies have provided the primary foundation of research in 
FASD, including the use of choline as a potential intervention, the sheep model provides 
important (if not unique) translational value.  The gestational period in sheep is relatively 
long (147 days) with the first trimester human equivalent extending from GD 4-41, the 
second trimester equivalent from GD 42-108, and the third trimester equivalent from GD 
109-132 [163].  Sheep also serve as a better model for humans in terms of the rate of brain 
development over gestation (the third trimester equivalent takes place in-utero similarly 
to humans and in contrast to the rodent model), the body and brain mass of the fetus and 
maternal-fetal physiology.  Techniques for instrumentation and experimental 
manipulation of the pregnant ewe are also now well established and feasible.  
The primary goal of this study was to model binge drinking in the first trimester 
and evaluate maternal choline supplementation administered throughout gestation as a 
preventative intervention for pregnancies at risk for FASD.  We used a heavy binge-like 
alcohol treatment to model repeated weekend binge drinking over the first trimester 
equivalent (GD 4-41), a pattern of drinking which is similar in women who abuse alcohol 
during pregnancy and a known risk factor for FASD [109, 111, 164].  A second goal of 
this study was to incorporate structural volumetrics with MRI to obtain brain volume 
measures like those done in human studies.  Although the use of MRI is routine in clinical 
veterinary medicine, quantitative 3-dimensional brain imaging for experimental studies 
has not been developed for use in sheep or other large animals.  Therefore many of the 
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tools for automated segmentation and quantification of various brain regions, commonly 
available in humans and rodents [165], have not been developed for experimental 
veterinary applications.  For this study, protocols and procedures were developed so that 
quantitative data from the sheep brain could be compared to measures routinely available 
from structural imaging in children with FASD [166].  Volumetric reductions have been 
demonstrated in the whole brain [167-169] and cerebellum [25, 42, 50, 170] and many 
studies have documented more selective changes in specific brain regions [171, 172]. 
Given our goal of implementing structural MRI protocols in the sheep model, our 
first approach was to obtain quantitative volumetric data of the whole brain of peripubertal 
lambs (six months old), a stage roughly equivalent to children entering puberty during 
early adolescence [124].  The cerebellum was also evaluated because it is easily segmented 
and it is known to be vulnerable to prenatal alcohol exposure [29, 42, 170, 173, 174].  We 
also quantified the volume of the pituitary as a potentially contrasting outcome, given the 
interesting findings reported in mouse models of binge-like gestational exposure.  In these 
studies, exposure either on gestational day 8 or on gestational days 12-16 yielded increased 
pituitary volume when assessed on gestational day 17 [175, 176].  Our fundamental 
hypothesis was that prenatal binge-like alcohol exposure over the first trimester equivalent 
would produce brain volume reductions detectable by MRI, directly modeling the 
microencephaly seen in children with FAS.  We also tested the hypothesis that maternal 
supplementation of choline in doses similar to those used in the CIFASD clinical trial, 
administered throughout the entire pregnancy, would protect against brain volume 
reductions.   
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III.3 Materials and methods 
III.3.1 Animals 
All animals and experimental procedures were approved by the Institutional 
Animal Care and Use Committee (IACUC) at Texas A&M University.  Prior to breeding, 
Suffolk ewes (aged 2-5 years) received multi-species Clostridium bacterin-toxoid 
(Covexin 8, Intervet/Schering-Plough Animal Health, Summit, NJ) 2 ml intramuscularly, 
albendazole (Valbazen Suspension 7.5 mg/kg, Pfizer Animal Health, New York, NY) 0.75 
ml/25 lb of body weight orally, and ivermectin (Ivomec Drench for Sheep 0.8%, Merial, 
Duluth, GA) 3 ml/26 lb body weight orally.  The day of mating, corresponding to when 
ewes were marked by the ram, was designated as GD 0.  Ewes were penned individually 
but had visual contact at all times with herd mates in adjacent pens in an environmentally 
regulated facility (22°C and a 12:12 light/dark cycle).  Pregnancy was confirmed 
ultrasonographically on GD 25 and ewes that were not pregnant were removed from the 
experiment.  Ewes were fed a “complete” ration (TAMU Ewe Ration, Nutrena, Cargill, 
Minneapolis, MN) designed to meet 100% National Research Council requirements (feed 
does not include choline) as calculated by ARIES (software version 2007, University of 
California, Davis) and had free access to drinking water.  Maternal food consumption was 
monitored daily.  All subjects consumed all feed offered. 
III.3.2 Choline dose development 
The aim of this study was to model the choline dose implemented in the CIFASD 
clinical trial, thus providing a strong basis for translational comparisons.  This study 
intentionally avoided the very high doses of choline used in the rodent models (~250 
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mg/kg per day) because they are ~25X higher (on a per kg basis) than the doses used in 
the Ukraine clinical trial (Coles et al., 2015).  The high choline doses often used in 
rodent studies are not likely to be used in clinical studies in pregnant women.  The 
choline dose we chose (10 mg/kg per day) is higher than what the current daily 
recommended dose is during human pregnancy (450 mg/day, ~6mg/kg per day).  In the 
CIFASD randomized clinical trial, alcohol-using and nondrinking women were 
randomized to one of three multivitamin/mineral supplement groups: none, 
multivitamins/minerals (MVM), and multivitamin/minerals plus choline.  The choline 
group was given a daily dose of 750 mg (~10 mg/kg per day), thus helping to guide the 
decision for the dose of choline used in the sheep model [162].  Higher daily doses of 
choline (on a mg/kg basis) may be given postnatally in humans [177], but this sheep 
model was developed to test choline supplementation during pregnancy with binge-like 
alcohol exposure during the first trimester equivalent.  Consequently, the dosing regimen 
used in this sheep model is both relevant and highly translational in respect to dose of 
choline and timing outcome of the children postnatally.  
In ruminants, choline is absorbed maximally in the abomasum and small intestine 
but it is often degraded in the rumen on its way.  Because of this, a commercially available 
microencapsulated choline supplement (designed for ruminants, primarily dairy cattle) 
was developed to allow the choline supplement to survive transfer through the rumen 
where it can be absorbed in the abomasum and small intestine (ReaShure® (choline 
chloride 28.8%), Balchem Corporation, New Hampton, NY).  To test this product in 
sheep, we fed 10 mg/kg of choline (based on weight of choline in ReaShure®) to ten non-
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pregnant ewes and then collected abomasal contents 30, 60 and 120 min after 
administration.  Choline levels in these samples were compared to the abomasal contents 
from 6 normal control animals that did not receive a choline supplement.  The level of 
choline in the abomasum was significantly higher in both the 30 min (848 nmol/ml) and 
60 min (627 nmol/ml) samples following choline administration with  ReaShure® as 
compared to the normal controls (557 nmol/ml) (p < 0.001).  Abomasal levels returned to 
baseline levels comparable to the normal controls at the 120 min time point.   
In a second preliminary study to evaluate plasma choline and betaine levels, 14 
pregnant ewes were assigned to three treatment groups: 1) saline control choline (SCC; 
isotonic saline (0.9%) during the 1st trimester plus 10 mg/kg/day choline until GD 133), 
2) heavy binge alcohol (HBA; 2.5 g/kg/treatment ethanol during the 1st trimester), and 3) 
heavy binge alcohol plus choline (HBC; 2.5 g/kg/treatment ethanol during 1st trimester 
plus 10 mg/kg/day choline until GD 133).  Plasma samples were collected on GD 134 and 
shipped frozen to the laboratory of Dr. C. Keen at University of California-Davis, who 
performed the choline analyses using mass spectroscopy.  Due to the limited number of 
available ewes, no saline control (SC; no choline) group was included for the GD 134 
samples.  However, a set of four normal control (NC) ewes were sampled on GD 147 to 
provide a comparative index of choline levels during late pregnancy.  For the GD 134 
samples, plasma choline levels were significantly higher (p < 0.05) in the two choline 
treated groups, SCC (5.55 ± 0.03 µM) and HBC (6.08 ± 0.62 µM), compared to the alcohol 
only group, HBA (3.94 ± 0.15 µM).  Betaine levels were significantly higher (p < 0.01) in 
the HBC group (210.1 ± 8.7 µM) compared to the SCC group (131.1 ± 1.1 µM) and the 
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HBA group (118.4 ± 12.8 µM).  For the NC plasma samples from GD 147, the levels for 
choline and betaine, respectively, were 5.06 ± 0.56 µM and 147.5 ± 21.8 µM.  Overall, 
these data suggest that the first trimester binge alcohol treatments may reduce choline 
levels and metabolism but that the choline supplementation appears to increase choline 
levels and choline metabolism in the HBC group.  Also, choline supplementation did not 
influence blood alcohol concentrations (~280 mg/dl) which indicates that the fetal 
exposure to alcohol with the maternal intravenous alcohol infusions was not altered by 
choline administration.    
III.3.3 Treatment groups 
Ewes (n = 44) were randomly assigned to one of five treatments - normal control 
(NC) group (n = 8 ewes), saline control group (SC; isotonic saline (0.9%)) group (n = 8 
ewes), saline control plus choline (SCC; isotonic saline (0.9%) plus 10 mg/kg/day choline) 
group (n = 6 ewes), heavy binge alcohol (HBA; 2.5 g/kg/treatment ethanol) group (n = 14 
ewes), and heavy binge alcohol plus choline (HBC; 2.5 g/kg/treatment ethanol plus 10 
mg/kg/day choline) group (n = 8).  The alcohol infusions in ewes modeled a weekend 
binge drinking pattern over the first trimester-equivalent in sheep (GD 4-41), with alcohol 
administered on three consecutive days per week, followed by four days without treatment 
(18 treatments in total). 
An intravenous catheter (16 ga., 5.25 inch Angiocath™; Becton Dickinson, Sandy, 
UT) was placed into the jugular vein of each ewe (except for the NC group) on GD 4.  
Beginning on this day, alcohol (2.5 g/kg body weight) or saline was administered 
intravenously via a pump over a 1-hour period (VetFlo® 7701B IV Vet Infusion Pump, 
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Grady Medical, Temecula, CA).  The alcohol solution was prepared by adding 95% 
ethanol to sterile 0.9% saline to achieve a 40% w/v alcohol solution.  Solutions were 
prepared under aseptic conditions and passed through a 0.2 μm bacteriostatic filter.  The 
saline control group received an infusion of isotonic saline (0.9%) that was equal in 
volume to the alcohol infusions.  Lambs produced from ewes in the five treatment groups 
that entered the imaging study included 8 NC lambs (2 females, 6 males), 8 SC lambs (4 
females, 4 males), 6 SCC lambs (2 females, 4 males), 14 HBA lambs (7 females, 7 males), 
and 8 HBC (2 females, 6 males).   
Ewes in the SCC and HBC treatment groups received 10 mg/kg oral choline 
(ReaShure® (choline chloride 28.8%; daily dose based on weight of choline, Balchem 
Corporation, New Hampton, NY) in which the supplement was mixed with their daily 
feed for the entirety of their pregnancy. 
III.3.4 Maternal blood alcohol concentration 
To measure peak BAC, blood was drawn from the jugular vein of each ewe one 
hour after alcohol infusions began on GD 6, 27, and 41, as previously described [109, 
128].  A 20 μl aliquot of blood was collected in a microcapillary tube and transferred into 
a vial containing 0.6 N perchloric acid and 4 mM n-propyl alcohol (internal standard) in 
distilled water.  The vial was tightly capped with a septum-sealed lid and stored at room 
temperature until analysis by headspace gas chromatography (Varian Associates model 
3900, Palo Alto, CA) within 24 h of collection.  
III.3.5 Postnatal management 
 At birth, newborn lambs were weighed and measured, their navels were dipped  
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in iodine (VetOne Stronger Iodine, 7%, MWI, Meridian, ID) and they were given 
oxytetracycline (Liquamycin®, LA-200®, 200 mg/ml, Pfizer Animal Health, New York, 
NY) 1 ml intramuscularly and selenium/vitamin E (BO-SE®, 1 mg/ml, Intervet/Schering-
Plough Animal Health, Summit, NJ) 0.5 ml subcutaneously.  Each ewe was checked for 
satisfactory milk production.  Lambs were closely monitored for nursing until weaning at 
2 months of age and weight gain and health status were recorded throughout the study.  At 
one and two months of age, lambs were vaccinated using multi-species clostridium 
bacterin-toxoid (Covexin 8, Intervet/Schering-Plough Animal Health, Summit, NJ) 2 ml 
intramuscularly.  Ewes were removed from the premises after weaning and lambs were 
housed in outdoor covered pens.  At weaning, lambs received moxidectin (Cydectin® Oral 
Drench for Sheep 0.1%, 1mg/ml, Boehringer Ingelheim, St. Joseph, MO) 0.2 ml/kg body 
weight orally, amprolium (Corid® 9.6% Oral Solution, Merial, Duluth, GA) 0.5 ml/kg 
orally once daily for ten days, and vitamin B1 (Thiamine Hydrochloride, 500 mg/ml, 
Rafter 8 Products, Calgary, Alberta, Canada) 1.5 ml subcutaneously once daily every third 
day for a total of four treatments.  Weaned lambs were fed a “complete” ration 
(Ringmaster Start-To-Finish Show Lamb Pellets, Nutrena, Minneapolis, MN) designed to 
meet 100% National Research Council requirements (feed does not contain choline) as 
calculated by ARIES (software version 2007, University of California, Davis), and had 
free access to drinking water.   
At six months of age, lambs were euthanized using sodium pentobarbital, 75 mg/kg 
intravenously (Beuthanasia®, Intervet/Schering-Plough Animal Health, Summit, NJ).  
The right and left internal carotid arteries were exposed in the cervical region.  They were 
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catheterized with tubing (2mm, Masterflex, Cole Parmer, Niles IL) and sutured to the 
adjacent fascia.  The corresponding right and left jugular veins were then exposed and cut 
transversely with a scalpel.  Saline was administered intravenously through the carotid 
arteries to perfuse the brain over an approximate 15-min period via a peristaltic pump 
(Masterflex, model 7014-20, Cole Parmer, Niles IL) until the fluid draining from the 
jugular veins was clear.  The brain was then perfused with formalin (SP® Buffered 10% 
Formalin, Cardinal Health, Dublin, OH) for an additional 15-min period.  The head was 
removed at the atlanto-occipital joint and an MRI was performed immediately. 
III.3.6 Magnetic resonance imaging 
The formalin-perfused lamb heads were scanned in a 15 channel knee coil (TxRx, 
Siemens Medical, USA) at the Texas A&M Institute for Preclinical Studies (TIPS) using 
a dedicated Siemens Magnetom Verio 3T MRI scanner (Siemens Medical, USA).  Images 
were acquired in the sagittal plane using the following Siemens MPRAGE (Ultrafast 
Gradient Echo 3D) sequence: TR = 2300 ms, TE = 3.79 ms, TI = 900 ms, FA = 9, Slice 
thickness = 0.43 mm, FoV = 256 mm x 256 mm, resolution = 0.4 mm x 0.4 mm x 0.4 mm, 
number of averages = 24, phase oversampling = 80%, and slice oversampling = 11.1%.  
Scan time was approximately 7 hours per specimen with ~288 2D slices per animal (Figure 
VIII).  
III.3.7 Volumetric analysis 
The whole brain volume and volumes of the cerebellum and the pituitary were 
manually segmented from each MRI slice (0.43 mm thickness) based on a previously 
described segmentation technique utilizing ITK Snap [178].  This software allows the 
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lamb brains to be viewed and segmented slice-by-slice simultaneously in three 
dimensions.  On each of the ~288 2D slices, the brain was manually segmented into the 
three regions of interest.  ITK Snap was used to reassemble individual segmented slices 
into a 3D reconstruction so that the volume could be calculated (Figure IX).  Absolute 
volumes were determined for the total brain, cerebellum, and pituitary gland individually.  
In addition, relative volumes were calculated by dividing the cerebellar and pituitary 
volume by the total brain volume from each subject and then multiplying by one hundred 
to determine a percentage of the total brain (a measure of cerebellar and pituitary effects 
relative to effects on whole brain). 
III.3.8 Statistical analysis 
Given the unequal numbers of males and females in the NC, SCC, and HBC groups 
and the low number of lambs of each sex across treatment groups overall, the power to 
detect potential sex differences was very limited.  The data was first screened for potential 
differences between males and females.  This was to determine whether the male and 
female data could be combined within groups for the purposes of statistical analyses 
without confounding the analysis of prenatal treatment.  The NC, SCC, and HBC groups 
each had only two females.  The within-group ranking of the data of those subjects was 
determined and each fell within the range of the majority sex of the group.  Therefore, the 
individual data did not skew the within-group distribution for any measure of the NC, SCC 
or the HBC groups.  For the two groups with equal numbers of males and females (SC and 
HBA), a two-way analyses of variance (ANOVA), with sex and treatment as the grouping 
factors was calculated.  None of the measures showed a significant main or interactive 
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effect of sex, so the data of males and females were combined within groups for 
subsequent analyses of variance. 
Statistical analysis was performed with SigmaPlot® (Version 12.5, Systat 
Software, Inc).  Data are presented as mean ± standard error of the mean (SEM).  
Treatment effects on measurements of total brain volume, cerebellum volume, pituitary 
volume, percentage cerebellum, and percentage pituitary were analyzed using a one-way 
ANOVA with a p < 0.05 level of significance.  Body weights at birth and at six months 
and whole brain, cerebellar and pituitary volumes were analyzed initially with a one-way 
ANOVA (including the normal controls).  In addition, those dependent variables were also 
analyzed with two-way ANOVAs (involving only four groups that were instrumented and 
infused (alcohol or saline) as grouping factors and omitting the NC group) to assess 
treatment effects of alcohol and choline supplementation.  Measures meeting the 
significance level on the univariate one-way ANOVAs were followed by pairwise 
comparisons among the five treatments (four treatments with the two-way ANOVAs) 
within each measure with multiple comparisons corrected by the Holm-Sidak method.   
III.4 Results 
III.4.1 Maternal blood alcohol concentration 
The mean ± SEM maternal BACs at the end of alcohol infusion (1 hour; point in 
time at which BACs are known to peak) were 280.5 ± 12.0 mg/dl in the heavy binge 
alcohol (HBA) group and 277.1 ± 9.0 mg/dl in the heavy binge alcohol plus choline (HBC) 
group.  There were no statistically significant differences in BACs between these two 
groups or across days of sampling. 
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Figure VIII.  Magnetic resonance imaging (MRI) derived images of a six-month-old lamb brain.  From left to 
right, representative transverse (or coronal/frontal in humans), dorsal (or horizontal/transverse/axial in 
humans), sagittal views show high resolution.     
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Figure IX.  Manually segmented MRI derived images of a normal six-month-old lamb brain.  Scans are color-
coded and reconstructed in 3D in ITK-Snap [178] by which volumes are calculated:  whole brain (red; transverse 
[coronal/frontal in humans] and dorsal [horizontal/transverse/axial in humans] views shown), cerebellum (blue; 
dorsal [horizontal/transverse/axial in humans] and sagittal views shown), and pituitary (green; sagittal and 
transverse [coronal/frontal in humans] views shown).     
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III.4.2 Birth and six-month-old body weights 
Birth weights by group were 5.16 ± 0.60 kg (NC), 5.74 ± 0.33 kg (SC), 6.15 ± 0.65 
kg (SCC), 4.34 ± 0.36 kg (HBA), and 4.94 ± 0.27 kg (HBC).  Although these group 
differences were statistically significant in the overall one-way ANOVA (F (4, 39) = 
2.650, p = 0.048), follow-up Holm-Sidak pairwise group comparisons showed no 
significant differences among the five treatment groups, in part because the NC group was 
highly variable and was intermediate between the two alcohol-exposed groups and the two 
saline control groups.  The two-way ANOVA on birth weight, with alcohol and choline 
supplementation as grouping factors (omitting the NC group), yielded a significant main 
effect of alcohol administration, confirming the reduced birth weights of the alcohol-
treated groups (F (1, 31) = 8.48, p = 0.007).  There were no main or interactive effects of 
choline supplementation on birth weight.   
For body weight at six months, there were no significant main or interactive effects 
of alcohol treatment or choline supplementation.  Six month weights by group were 28.87 
± 3.74 kg (NC), 38.72 ± 4.04 kg (SC), 34.00 ± 3.07 kg (SCC), 33.22 ± 1.47 kg (HBA), 
and 33.75 ± 1.90 kg (HBC).  The two-way ANOVA on six month body weights showed 
no significant main or interactive effects of alcohol treatment or choline supplementation.   
III.4.3 Whole brain volume 
As shown in Figure X (top row), significant effects among the five treatment 
groups were evident in the whole brain volume measures (one-way ANOVA, F (4, 39) = 
9.575, p < 0.001).  Follow-up pairwise comparisons (Holm-Sidak corrected) confirmed 
that the whole brain volumes of the two alcohol-exposed groups (HBA; HBC) were 
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significantly reduced relative to the three control groups (NC; SC; SCC).  There were no 
significant differences between the heavy binge alcohol groups, with (HBC) and without 
(HBA) choline supplementation, or among the three control (NC, SC, SCC) groups.  In 
addition, the two-way ANOVA with alcohol and choline supplementation as grouping 
factors (omitting the NC group) yielded a significant main effect of alcohol 
administration, confirming the reduced whole brain volume of the alcohol-treated groups 
(F (1, 32 ) = 35.67, p < 0.001).  There were no main or interactive effects of choline 
supplementation on whole brain volume. 
III.4.4 Cerebellar and pituitary volumes 
In one-way ANOVAs for absolute volumes of the cerebellum and pituitary, there 
were no significant differences among the five treatment groups in either the cerebellum 
(F (4, 39) = 2.280, p = 0.078) or pituitary (F (4, 39) = 0.774, p = 0.549) (Figure X; top 
row).  There were also no significant differences in the relative volume, expressed as 
percent of the total brain, for the cerebellum (F (4, 39) = 0.959, p = 0.441) and pituitary 
(F (4, 39) = 1.104, p = 0.368) (Figure X; bottom row).  However, with a two-way ANOVA 
for cerebellar volume involving the four prenatally infused groups (alcohol or saline, 
omitting the NC group), the main effect of alcohol administration reached statistical 
significance, confirming that alcohol reduced cerebellar volumes in the HBA and HBC 
groups (F (1, 32) = 9.29, p = 0.005).  There were no main or interactive effects of choline 
supplementation on the cerebellar volume.  For pituitary volume, the two-way ANOVA 
yielded no significant main or interactive effects of alcohol treatment or choline 
supplementation.   
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Figure X.  Treatment effects on the whole brain, cerebellum, and pituitary volumes 
(top row) and treatment effects on the cerebellum and pituitary as a percentage of 
total brain size (bottom row).  The y axis (top row) indicates the mean volume (+ 
SEM) in mm3 for whole brain volume, cerebellum and pituitary.  Note the scale for 
the whole brain in the top left panel (maximum of 140,000 mm3) differs from that of 
the cerebellum and pituitary in the two top right panels (maximum of 14,000 mm3).  
The bottom panel is the percent total brain (maximum 14%).  The ANOVA α level 
was 0.05, followed by the Holm-Sidak method for pairwise comparisons (p < 0.05).  
Significant group differences are indicated within each panel.  An asterisk (*) 
indicates that the volumes of three control groups (NC, SC. SCC) were significantly 
greater than the two alcohol-exposed groups (HBA and HBC); NC, SC, and SCC did 
not differ from each other, and HBA and HBC did not differ from each other.   
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 III.5 Discussion 
The use of choline as an interventional strategy to lessen the effects of prenatal 
alcohol exposure on the developing fetus has been studied prenatally and postnatally in 
the rodent, showing some beneficial improvements in memory, behavior and cognition 
[153, 156, 158-160].  Currently, there is one published randomized clinical trial (from the 
CIFASD initiative) involving prenatal choline supplementation as a component of a 
multivitamin and mineral (MVM) supplementation trial (Coles et al., 2015).  That study 
indicated benefits of the MVM supplements in infants on Bayley Mental Development 
scores (particularly in males), but there were no significant additional benefits of choline 
beyond these scores.  Also, the MVM supplements did not prevent lower birthweights and 
head circumferences in the prenatal alcohol exposed infants.  The current findings in this 
sheep model suggest that the reduced brain size and lower birth weights associated with 
first trimester binge alcohol exposure are not likely ameliorated with the dose of choline 
used (matched between the sheep study and the clinical trial), even if the choline 
supplements were started early in pregnancy and continued until birth.   
Choline doses used in this study (10 mg/kg per day) were carefully matched to the 
dose used in the CIFASD clinical trial.  However, on a mg/kg basis, this dose is more than 
an order of magnitude lower than the doses used in rodent studies that showed benefits in 
neurobehavioral and physical developmental outcomes (typically ~250 mg/kg per day).  
This raises the appropriate question as to whether the dose of choline needed to produce 
beneficial effects needs to be much higher than is currently used for clinical interventions.  
The failure of maternal choline supplementation to mitigate brain volume reductions 
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associated with prenatal alcohol exposure suggests that any potential cognitive, cellular, 
and other benefits of choline in the sheep model of FASD, prenatally or postnatally, 
remains to be determined.  Other complex questions about pharmacokinetics, metabolism 
and bioavailability of choline (as a nutraceutical) across species (rodents, sheep and 
humans) also need to be addressed in future studies.  Additionally, most women are likely 
to consume varying amounts of choline in their daily diet.  In the Ukraine clinical trial, the 
supplement they received is in addition to whatever amount of choline is present in their 
daily diet (Coles et al., 2015).  Since the choline requirements in ruminants are not well 
established, most commercial rations do not contain choline.  Therefore we can only say 
with certainty that the ewes received the 10 mg/kg/day choline for the duration of their 
pregnancy.  If doses of choline (as a nutraceutical, rather than just to correct a deficiency) 
need to be high (as used in the rodent studies), this may limit the feasibility in clinical 
settings due to tolerability.  Currently, there is one study in children (aged 2-5 years old) 
with FASD that assessed tolerability and potential adverse effects associated with choline 
supplementation [177] but this information is not known for pregnant women.     
To our knowledge, there are no published human or animal model studies that 
evaluate volumetric structural brain measures with choline supplementation given either 
prenatally or postnatally with heavy binge-like alcohol exposure.  The current study of 
lambs born to ewes given alcohol during the first trimester equivalent of gestation was 
intended to assess quantitative measures of three easily obtained structural volumes known 
to be affected by prenatal alcohol exposure in peripubertal lambs (modeling early 
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adolescent children) and to determine whether prenatal choline supplementation has 
measureable effects on brain volume.       
This is the first report of quantitative MRI showing reduced total brain volume in 
six-month-old lambs modeling heavy week-end binge drinking over the first trimester.  
Our finding of total brain volume reductions in alcohol-exposed lambs are consistent with 
numerous neuroimaging studies in children and young adults with known prenatal alcohol 
exposure and FASD regardless of whether they meet the full diagnostic criteria for FAS 
[166].  Brain imaging studies in murine models have also shown whole brain volume 
reductions (O'Leary-Moore, Parnell et al., 2010; [176]; [179].  Importantly, the prenatal 
alcohol-induced reductions in brain volumes observed in this sheep model occurred with 
a weekend binge exposure model that produced BAC profiles consistent with binge 
drinking (~280 mg/dl). 
Significant reductions in absolute cerebellum volumes reported in this study 
(compared to saline-infused controls) were consistent with neuroimaging findings in 
humans [25, 42, 50, 170] while a contrasting study in rats found that cerebellar weight, 
volume, Purkinje cell number and granule cell density were only reduced in the third 
trimester and all three trimester exposure models.  Moreover, data from the first trimester 
exposure did not differ from the control groups [180].  It is reasonable to conclude that 
cerebellar volume reduction is more severe when alcohol exposure extends beyond the 
first trimester, but even first trimester exposure can lead to significant cerebellar deficits.  
There would be value in analyzing regional volumes of other cortical and subcortical brain 
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structures to determine whether they are more susceptible to first trimester alcohol 
exposure.   
Consistent with prior murine studies [175, 176, 179, 181, 182], neither absolute 
nor relative pituitary volume differed significantly among the five treatment groups.  
However, two studies in GD 17 mice showed an increased pituitary volume following 
exposure to alcohol during GD 8 and 12-16 [175, 176].  
Limitations with this model include increased time, effort, and expense associated 
with accruing representative numbers of sheep for evaluation.  Also, because of the high 
expense of anesthesia and long MRI scan times to acquire high resolutions images, 
animals were euthanized and their brains were perfused with formalin immediately prior 
to scanning.  Although possible, we do not believe that fixation would differentially affect 
alcohol exposed brains versus normal control brains. 
In conclusion, our findings confirm that heavy binge alcohol exposure in the first 
trimester in the sheep model produces significant brain volume reductions in peripubertal 
lambs and that maternal choline supplementation at 10 mg/kg/day failed to prevent these 
reductions.  MRI-based volumetric findings in the brain are comparable to outcomes 
reported for children and adolescents with FASD, further supporting the translational 
advantages of the sheep model.  The lack of brain volume protection by gestational choline 
treatments suggest that even though choline supplementation in preclinical rodent studies 
benefits neurodevelopmental and cognitive functions, it may not spare brain volume.  
Future studies in this sheep model will evaluate behavioral and additional brain structure 
volumetrics.  
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CHAPTER IV  
MAGNETIC RESONANCE IMAGING AND HISTOPATHOLOGY 
CORRELATION IN THE GOLDEN RETRIEVER MODEL FOR DUCHENNE 
MUSCULAR DYSTROPHY 
 
IV.1 Overview 
Duchenne muscular dystrophy (DMD) is an X-linked recessive disorder caused by 
mutations in the dystrophin gene.  Affected boys have repeated cyclic events that include 
skeletal muscle necrosis, degeneration, attempts at regeneration, muscle atrophy and 
eventual replacement of skeletal muscle tissue by fibrofatty tissue.  Golden retriever 
muscular dystrophy (GRMD) is genetically homologous and affected dogs demonstrate 
similar pathologic features.  Magnetic resonance imaging (MRI) has been utilized in 
natural history and treatment studies in both of DMD and GRMD.  Correlative registration 
studies of histological images to three-dimensional imaging modalities like MRI are 
essential to quantitatively analyze skeletal muscle changes.  This study had three central 
aims, 1) register and correlate corresponding histology and MR images of the pectineus 
muscle using a novel registration technique, 2) compare a commercially available 
histology segmentation program (Aperio) to a novel custom algorithm for automated 
histomorphometry, and 3) compare outputs from 4.7T research and 3T clinical scanners 
to determine potential clinical application of the registration techniques.  We found that 
histology and MR images co-registered but metrics were poorly correlated.  Moreover, the 
custom algorithm and Aperio software provided similar results and with optimization, a 
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fully automated algorithm could be applied to current research.  Finally, only T1 values 
were correlated between the 4.7T or 3T scanners.  Neither T1 values, nor any of the 3T 
metrics correlated with histologic segmentations.  
IV.2 Introduction 
Duchenne muscular dystrophy (DMD) is an X-linked recessive disorder caused by 
mutations in the dystrophin gene.  Resulting muscle cell membrane fragility leads to 
recurring bouts of myofiber necrosis, with progressive replacement of muscle by fat and 
connective tissue [73, 183, 184].   
 Numerous therapies are being developed for DMD to either restore dystrophin 
expression or reverse secondary effects such as fibrosis and inflammation [185-187].  
Traditionally, skeletal muscle biopsies have been considered the “gold standard” for not 
only diagnosis but also as an outcome parameter in clinical trials. Skeletal muscle 
pathology data in children are often limited to small biopsy samples [188], which may not 
be representative of the segmental nature of lesions and their muscle-wide distribution 
[189-191].     
 Magnetic resonance imaging (MRI) has been increasingly utilized as a non-
invasive biomarker to evaluate DMD patients.  Results from quantitative MRI studies have 
been shown to correlate with disease related parameters [192, 193].  While MRI allows 
numerous muscles to be assessed without the need for biopsy, few studies have correlated 
findings with histopathology.  In one such study, Kinali et al. (2011) used semiquantitative 
indices to correlate MRI and histopathologic changes in the extensor digitorum brevis 
(EDB) of DMD patients.   
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 Animal models play a major role in preclinical studies to determine treatment 
efficacy and side effects.  The phenotype of dogs with golden retriever muscular dystrophy 
(GRMD) more closely mirrors that of affected boys compared to the mildly affected mdx 
mouse.  Dystrophic dogs have a larger body, longer lifespan and early onset of disease in 
keeping with DMD [194].  Similar to humans, skeletal muscles lack dystrophin and 
undergo cycles of necrosis with eventual replacement by abundant fibrous tissue and some 
fat.  A number of studies have defined MRI features in both GRMD natural history and 
preclinical trials [195, 196].       
Although MRI is becoming a mainstay in DMD and animal model treatment trials, 
interpretation has been limited by a lack of systematic studies to correlate changes with 
histopathologic lesions.  This study partially addressed this gap through three interrelated 
aims: a) quantitatively evaluate microscopic sections of muscle using a commercially 
available pathology software program (Aperio) and compare the results with those from a 
digitally matched corresponding MR image through a custom registration technique; b) 
develop a custom algorithm that automatically segments histopathology slides to counter 
the tedious and subjective nature of manual segmentation, and c) determine whether a 
clinical scanner could provide meaningful in vivo data by comparing output parameters 
from pectineus muscle scans performed on both a 3T clinical and 4.7T research scanner.  
We hypothesized that findings from co-registered MR and histology images would 
correlate, that comparable data would be provided by a custom automated algorithm and 
commercially available software program (Aperio), and that the 3T and 4T scanners would 
provide similar results, supporting use of this technique clinically.    
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IV.3 Materials and methods 
IV.3.1 Animals 
Dogs from a GRMD colony at Texas A&M University were cared for and assessed 
according to principles outlined in the National Research Council Guide for the Care and 
Use of Laboratory Animals.  Their use was covered by Texas A&M Institutional Animal 
Care and Use Committee (IACUC) protocol, Standard Operating Procedures—Canine X-
Linked Muscular Dystrophy (TAMU IACUC 2015-0110). The pectineus muscle was 
harvested post-mortem from nine GRMD dogs.  Each muscle was placed into an 
individually labeled container with formalin (SP® Buffered 10% Formalin, Cardinal 
Health, Dublin, OH).   
IV.3.2 Magnetic resonance imaging 
We were motivated to reduce motion artifacts caused by vibrations that occur 
during high-resolution scans and to more closely simulate an in-vivo scan.  Prior to 
scanning, each formalin fixed pectineus muscle was embedded in a 50ml conical tube 
(VWR, Radnor, PA) using a 0.08% agarose (Apex Bioresearch Products, Agarose General 
Purpose, San Diego, CA) gel (0.8 grams agarose in 100ml water).  Each dog was identified 
with a numerical value and all investigators were blinded to identity.  Samples were 
scanned first with the 3T scanner and then the 4.7T scanner.  MRI metrics analyzed 
included T1, T2, water, fat, fractional anisotropy (FA), and apparent diffusion coefficient 
(ADC).   
Embedded pectineus muscles were scanned in a 7cm ring coil (Siemens Medical, 
USA) at the Texas A&M College of Veterinary Medicine, Veterinary Medical Teaching 
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Hospital using a dedicated Siemens Magnetom Verio 3T MRI scanner (Siemens Medical, 
USA).  Images were acquired in the transverse plane using the following Siemens 
T1_TSE_Dixon sequence: TR = 710 ms, TE = 38 ms, FA = 140, slice thickness = 2.0 mm, 
FoV = 50 mm x 50 mm, resolution = 0.2 mm x 0.2 mm x 2.0 mm, number of averages = 
6, phase oversampling = 0%.  Scan time was approximately 36 minutes per specimen with 
~30 2D slices per sample.  The next sequence used was T1_MAP sequence: TR = 16.7 
ms, TE = 5.51 ms, FA = 4, 21, slice thickness = 1.7 mm with a 20% gap, FoV = 50 mm x 
50 mm, resolution = 0.2 mm x 0.2 mm x 1.7 mm, number of averages = 9, phase 
oversampling = 10%.  Scan time was approximately 51 minutes per specimen with ~30 
2D slices per sample.  The third sequence used was T2_MAP sequence: TR = 3500 ms, 
TE = 15, 30, 45, 60, 75, 90 ms, FA = 180, slice thickness = 2mm, FoV = 50 mm x 50 mm, 
resolution = 0.2 mm x 0.2 mm x 2.0 mm, number of averages = 1, phase oversampling = 
0%.  Scan time was approximately 15 minutes per specimen with ~30 2D slices per 
sample.  The fourth sequence used was the RESOLVE DTI (Multi-shot echo planar 
imaging diffusion tensor imaging) sequence: TR = 4700 ms, TE = 68, 96 ms, FA = 180, 
slice thickness = 2 mm, FoV = 95 mm x 95 mm, resolution = 1.7 mm x 1.7 mm x 2.0 mm, 
number of averages = 1, phase oversampling = 0%, number of diffusion encoding 
directions = 13.  Scan time was approximately 23 minutes per specimen with ~30 2D slices 
per sample. 
These pectineus samples were next scanned in a 40 cm bore 4.7T Varian Bruker 
scanner equipped with an in-house developed birdcage coil.  The T1-weighted images 
were acquired with TR = 268 ms, TE = 6.1 ms, FA = 21° and 72°, slice thickness = 1 mm, 
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and a matrix size of 256 × 256 over a 30 × 30 mm2 field of view (FOV), resolution = 0.12 
mm x 0.12 mm and number of averages = 4.  Four 5-slice acquisitions were interleaved to 
obtain 20 slices from each sample.  Scan time was approximately 38 minutes per 
specimen.  The T2-weighted images were acquired using a spin echo sequence with TR = 
3s, TE = 20, 40, 60, 80 ms, slice thickness = 1 mm, matrix size = 256 x 256, FOV = 30 × 
30 mm2, slice thickness = 1mm, resolution 0.12 mm x 0.12 mm and number of averages 
= 1.  Scan time was approximately 62 minutes per specimen.  A third sequence, a three 
point Dixon sequence was acquired with TR = 1s, TE = 40 ms, slice thickness = 1mm and 
matrix size was 256 × 256 over 30 × 30 mm2 of FOV and resolution = 0.12 mm × 0.12 
mm.  Scan time was approximately 26 minutes per specimen. A fourth sequence, a DTI 
(diffusion tensor imaging) sequence was acquired with TR = 3s, TE 68 ms, slice thickness 
= 1mm, and a matrix size = 128 x 128 over a 30 mm × 30 mm FOV, gradient = 8.5 
Gauss/cm, δ (duration of gradient) = 7 ms, Δ (time between two gradients) = 25 ms, 
resolution = 0.23 mm × 0.23 mm and slice thickness = 1 mm, number of diffusion 
encoding directions = 6.  Scan time was approximately 69 minutes per specimen.  Twenty 
one millimeter thick transverse slices with a one millimeter slice gap were acquired to 
cover a 40 mm region including the middle of the muscle.   
   Upon completion of both scans, the pectineus muscle was removed from the 
agarose gel, rinsed in deionized water and placed back into formalin for storage. 
IV.3.3 Histologic sectioning and processing of pectineus samples 
The pectineus muscles were sectioned mid-muscle and the central cut was placed 
face down into a tissue cassette.  Fixed tissues were paraffin-embedded and processed 
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routinely.  Five micrometer mid-muscle sections were trichrome stained.  Histology slides 
were scanned on a NanoZoomer 2.0-HT slide scanning system to create digital files at a 
maximum 40x optical zoom (Hamamatsu, Japan).  
IV.3.4 MR image and histology image registration 
One of the authors (AE) exported the histology images at 10X magnification using 
NDPITools [197].  A mask was created using GIMP (GNU Image Manipulation Program, 
University of California, Berkley) and then images were resized, cropped, edited, 
retouched and authored with an open-source software program.  An edge fitting tool based 
on a live-wire boundary extraction algorithm [198] was used to create a mask containing 
the segmented foreground of the histologic section.  Masking removed the background 
portion of the scanned slide and artifacts around the borders of the muscle tissue (Figure 
XI, B).  Histology images were imported into Matlab® for further processing.  The in-
plane resolution of the histology image was down-sampled to match the MRI resolution 
because the histology voxel resolution differed tremendously from the MRI voxel 
resolution (0.91 µm x 0.91 µm x 5.00 µm versus 0.12 mm x 0.12 mm x 1.00 mm).  
Histology images were then converted to HSV images and an adaptive histogram 
equalization algorithm was used to improve the texture of the hue images (Figure XI, C).  
Initial orientation of the histology image (trichrome) was determined by transforming it in 
the 3D MRI volume.  Then, an optimization algorithm was used to refine the 
transformation parameters and generate an oblique MRI slice corresponding to the 
histology slice (Figure XI, D).  Red channel and texture enhanced hue images were 
compared with the MRI images to increase visual similarity using affine transformation 
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(Figure XI, E).  Finally, a non-rigid B-spline transformation was used to register the 
histology slice to the oblique MRI slice using Elastix registration software (Figure XI, F).  
The average T1, T2, water, fat, FA, and ADC data points were recorded from the MR 
image corresponding to the histopathology image that was graded (Figure XI).  
IV.3.5 Aperio ImageScope segmentation of histopathology 
Histology images were analyzed for compartment percentages of muscle, fibrous 
tissue, fat, and interstitial space.  The interstitial space is defined as the non-staining white 
space in the slide and it included the fat and artefactual tears or spaces created by 
sectioning. 
A board-certified veterinary anatomic pathologist (SMB) graded the pectineus 
digital histology images using an edited version of the positive pixel count algorithm 
(version 9.1) embedded in the Aperio ImageScope software (version 12.1.0.5029, Leica 
Biosystems, Nussloch, Germany).  The algorithm parameters were optimized for 
trichrome staining: hue value = 0.66, hue width = 0.30, color saturation threshold = 0.04, 
lwp (high) = 200, lwp (low) = lp (high) = 200, and lp (low) = lsp (high) = 200. 
The tissue (Figure XII, A) was first manually outlined with the pen tool in Aperio 
and artefactual tissue tears and creases were subtracted with the negative pen tool (Figure 
XII, B).  The “manually outlined area” of the remaining tissue was calculated by the 
software in µm2 and converted to mm2 by dividing by one million.  The Aperio algorithm 
output analyzes the manually segmented area composed of the numbers of strong pixels 
(Nsp; red staining with trichrome or fibrous/collagen tissue), negative pixels (Nn; blue 
staining with trichrome or muscle tissue), total of strong positive and negative pixels  
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Figure XI.  Stepwise example of the registration process.  A-F, Images show the 
pectineus muscle sectioned at mid-muscle (A), the corresponding trichrome digital 
image (B), the trichrome image from step B, converted to grayscale (C), and the 
corresponding MR image (D).  Red and green channels were applied to both C 
(green) and D (red) to allow for alignment (E) and, the final trichrome digital image 
was registered with the MR image (F). 
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(NTotal = Nn + Nsp), pixel area (mm2; area of one pixel) and total pixel area (mm2; ATotal 
= (Nn + Nsp)*pixel area) (Figure XII, C).  Fat within each muscle was manually 
segmented with the pen tool and the areas were added to get total fat in mm2 by taking 
µm2 and dividing by one million (Figure XII, D). 
𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀 𝑜𝑜𝑀𝑀𝑜𝑜𝑀𝑀𝑜𝑜𝑀𝑀𝑜𝑜𝑜𝑜 𝑀𝑀𝑎𝑎𝑜𝑜𝑀𝑀 𝑜𝑜𝑀𝑀 𝑚𝑚𝑚𝑚2 = 𝑀𝑀𝑎𝑎𝑜𝑜𝑀𝑀 𝑜𝑜𝑀𝑀 µ𝑚𝑚21,000,000  
𝑁𝑁𝑁𝑁𝑜𝑜𝑜𝑜𝑀𝑀𝑀𝑀 = 𝑁𝑁𝑀𝑀 + 𝑁𝑁𝑁𝑁𝑁𝑁 
𝐴𝐴𝑜𝑜𝑜𝑜𝑜𝑜𝑀𝑀𝑀𝑀 = (𝑁𝑁𝑀𝑀 + 𝑁𝑁𝑁𝑁𝑁𝑁) ∗ 𝑁𝑁𝑜𝑜𝑝𝑝𝑜𝑜𝑀𝑀 𝑀𝑀𝑎𝑎𝑜𝑜𝑀𝑀1,000,000  
The following equations were calculated to determine areas of muscle, fibrous tissue, fat 
and interstitial space in each manually segmented pectineus muscle analyzed.  
𝐴𝐴𝑎𝑎𝑜𝑜𝑀𝑀 𝑜𝑜𝑜𝑜 𝑚𝑚𝑀𝑀𝑁𝑁𝑚𝑚𝑀𝑀𝑜𝑜 𝑚𝑚𝑚𝑚2 = 𝑁𝑁𝑀𝑀 ∗ 𝑁𝑁𝑜𝑜𝑝𝑝𝑜𝑜𝑀𝑀 𝑀𝑀𝑎𝑎𝑜𝑜𝑀𝑀 
𝐴𝐴𝑎𝑎𝑜𝑜𝑀𝑀 𝑜𝑜𝑜𝑜 𝑜𝑜𝑜𝑜𝑓𝑓𝑎𝑎𝑜𝑜𝑀𝑀𝑁𝑁 𝑜𝑜𝑜𝑜𝑁𝑁𝑁𝑁𝑀𝑀𝑜𝑜 𝑚𝑚𝑚𝑚2 = 𝑁𝑁𝑁𝑁𝑁𝑁 ∗ 𝑁𝑁𝑜𝑜𝑝𝑝𝑜𝑜𝑀𝑀 𝑀𝑀𝑎𝑎𝑜𝑜𝑀𝑀 
𝐴𝐴𝑎𝑎𝑜𝑜𝑀𝑀 𝑜𝑜𝑜𝑜 𝑜𝑜𝑀𝑀𝑜𝑜 𝑚𝑚𝑚𝑚2 = 𝑚𝑚𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀 𝑁𝑁𝑜𝑜𝑠𝑠𝑜𝑜𝑚𝑚𝑜𝑜𝑀𝑀𝑜𝑜𝑜𝑜𝑜𝑜 𝑀𝑀𝑎𝑎𝑜𝑜𝑀𝑀 𝑜𝑜𝑜𝑜 𝑜𝑜𝑀𝑀𝑜𝑜 𝑜𝑜𝑀𝑀 µ𝑚𝑚21,000,000  
𝐴𝐴𝑎𝑎𝑜𝑜𝑀𝑀 𝑜𝑜𝑜𝑜 𝑜𝑜𝑀𝑀𝑜𝑜𝑜𝑜𝑎𝑎𝑁𝑁𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑀𝑀𝑀𝑀 𝑁𝑁𝑁𝑁𝑀𝑀𝑚𝑚𝑜𝑜 𝑚𝑚𝑚𝑚2 = 𝑚𝑚𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀𝑀 𝑜𝑜𝑀𝑀𝑜𝑜𝑀𝑀𝑜𝑜𝑀𝑀𝑜𝑜 𝑀𝑀𝑎𝑎𝑜𝑜𝑀𝑀 𝑜𝑜𝑀𝑀 𝑚𝑚𝑚𝑚2
− (𝑀𝑀𝑎𝑎𝑜𝑜𝑀𝑀 𝑜𝑜𝑜𝑜 𝑚𝑚𝑀𝑀𝑁𝑁𝑚𝑚𝑀𝑀𝑜𝑜 𝑚𝑚𝑚𝑚2 + 𝑀𝑀𝑎𝑎𝑜𝑜𝑀𝑀 𝑜𝑜𝑜𝑜 𝑜𝑜𝑜𝑜𝑓𝑓𝑎𝑎𝑜𝑜𝑀𝑀𝑁𝑁 𝑜𝑜𝑜𝑜𝑁𝑁𝑁𝑁𝑀𝑀𝑜𝑜 𝑚𝑚𝑚𝑚2 + 𝑀𝑀𝑎𝑎𝑜𝑜𝑀𝑀 𝑜𝑜𝑜𝑜 𝑜𝑜𝑀𝑀𝑜𝑜 𝑚𝑚𝑚𝑚2) 
The following equations were calculated to determine the percentage of muscle, fibrous 
tissue, fat and interstitial space in each manually segmented pectineus muscle analyzed.  
% 𝑚𝑚𝑀𝑀𝑁𝑁𝑚𝑚𝑀𝑀𝑜𝑜 = 𝐴𝐴𝑎𝑎𝑜𝑜𝑀𝑀 𝑜𝑜𝑜𝑜 𝑚𝑚𝑀𝑀𝑁𝑁𝑚𝑚𝑀𝑀𝑜𝑜 𝑚𝑚𝑚𝑚2
𝐴𝐴𝑁𝑁𝑜𝑜𝑜𝑜𝑀𝑀𝑀𝑀
∗ 100 
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% 𝑜𝑜𝑜𝑜𝑓𝑓𝑎𝑎𝑜𝑜𝑀𝑀𝑁𝑁 𝑜𝑜𝑜𝑜𝑁𝑁𝑁𝑁𝑀𝑀𝑜𝑜 = 𝐴𝐴𝑎𝑎𝑜𝑜𝑀𝑀 𝑜𝑜𝑜𝑜 𝑜𝑜𝑜𝑜𝑓𝑓𝑎𝑎𝑜𝑜𝑀𝑀𝑁𝑁 𝑜𝑜𝑜𝑜𝑁𝑁𝑁𝑁𝑀𝑀𝑜𝑜 𝑚𝑚𝑚𝑚2
𝐴𝐴𝑁𝑁𝑜𝑜𝑜𝑜𝑀𝑀𝑀𝑀
∗ 100 
% 𝑜𝑜𝑀𝑀𝑜𝑜 = 𝐴𝐴𝑎𝑎𝑜𝑜𝑀𝑀 𝑜𝑜𝑜𝑜 𝑜𝑜𝑀𝑀𝑜𝑜 𝑚𝑚𝑚𝑚2
𝐴𝐴𝑁𝑁𝑜𝑜𝑜𝑜𝑀𝑀𝑀𝑀
∗ 100 
% 𝑜𝑜𝑀𝑀𝑜𝑜𝑜𝑜𝑎𝑎𝑁𝑁𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑀𝑀𝑀𝑀 𝑁𝑁𝑁𝑁𝑀𝑀𝑚𝑚𝑜𝑜 = 𝐴𝐴𝑎𝑎𝑜𝑜𝑀𝑀 𝑜𝑜𝑜𝑜 𝑜𝑜𝑀𝑀𝑜𝑜𝑜𝑜𝑎𝑎𝑁𝑁𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑀𝑀𝑀𝑀 𝑁𝑁𝑁𝑁𝑀𝑀𝑚𝑚𝑜𝑜 𝑚𝑚𝑚𝑚2
𝐴𝐴𝑁𝑁𝑜𝑜𝑜𝑜𝑀𝑀𝑀𝑀
∗ 100 
 
IV.3.6 Custom algorithm segmentation of histopathology 
One of the authors (SM) first converted histology images from the original NDPI 
files to TIFF files.  A border was drawn around the muscle tissue using GIMP (Figure XII, 
F).  TIFF images were then used for both the registration to MR images described 
previously and also in the custom algorithm so that both methods of analysis used the 
same image and borders.  A custom, automated algorithm to segment the muscle, fibrous 
tissue and interstitial space was developed for this study.  This novel algorithm included 
an estimate of inevitable segmentation error given the vast size of the NanoZoomer 
histology images.  Adaptive thresholding was also incorporated in the algorithm to 
compensate for variations in trichrome staining between samples.  This algorithm 
calculated the percent muscle, percent fibrous tissue and the percent interstitial space 
within each section (Figure XII, G).    
IV.4 Statistical analysis 
Descriptive statistics were carried out wherever appropriate by using SigmaPlot® 
(Version 13, Systat Software, Inc.).  Data are presented as mean ± standard error of the 
mean (SEM).  The following data sets were evaluated: 1) 4.7T and 3T MRI measures (T1,
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Figure XII.  Stepwise example of Aperio histology segmentation and custom algorithm segmentation.  A-D, Images from 
Aperio show the digitalized muscle (A), the manually drawn border (B), the edited Aperio algorithm to quantitate muscle 
(blue) and fibrous tissue (red) (C), and the manually segmented fat (red, see arrows) (D).  E-G, Images from the custom 
algorithm show the digitalized muscle (E), the mask created to crop the outside borders (F), and the custom algorithm 
to quantitate muscle (red) and fibrous tissue (blue) (G).
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T2, water, fat, FA, ADC) and histology measures (muscle, fibrous tissue, interstitial space, 
fat), 2) Aperio histology and custom algorithm histology measures (muscle, fibrous tissue, 
interstitial space, fat), and 3) 4.7T and 3T MRI measures (T1, T2, water, fat, FA, ADC).  
The MRI metrics and histology segmentations were assessed by calculating the Pearson 
correlation coefficient (r).  The strength of correlation coefficients was assessed by the 
criteria of Portney and Watkins [199]:  little to no relationship (r ≤ 0.25), fair degree of 
relationship (r = 0.26 - 0.50), moderate to good relationship (r = 0.51 - 0.75), and good to 
excellent relationship (r ≥ 0.76).  Measures from the Aperio and custom algorithm 
segmentation methods as well as measures from the 4.7T and 3T MRI methods were 
assessed by calculating the Bland-Altman analysis and intraclass correlation coefficient 
(ICC).  A range of agreement was defined as mean bias ± 2.0 SD for the Bland-Altman 
analysis [200-202].  ICC results were interpreted based on guidelines by Fleiss [203]: 
excellent relationship (r > 0.75), fair to good relationship (r = 0.40 - 0.75), and poor 
relationship (r < 0.40).   
IV.5 Results 
IV.5.1 Correlations between histology and MRI 
Pearson correlations between histology and MRI measures are listed in table IX.  
Significant correlations were identified between both Aperio fat (%) and custom muscle 
(%) for 4.7T water (p = <0.001; 0.004, respectively), fat (p = <0.001; 0.004, respectively), 
and FA (p = 0.005; 0.020, respectively).  Custom interstitial space (%) correlated 
positively with 4.7T ADC (x10-3 mm2/s) (p = 0.020).  Measures from the 3T scanner did 
not correlate with any of the histology measures. 
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Table IX.  Pearson correlations between MRI and histology measures 
  4.7T 3T 
 T1 
(ms) 
T2 
(ms) 
Water  
(%) 
Fat  
(%) FA 
ADC  
(x10-3 mm2/s) 
T1 
(ms) 
T2 
(ms) 
Water 
(%) 
Fat 
(%) FA 
ADC  
(x10-3 mm2/s) 
Aperio % Muscle 0.080 0.392 0.649 -0.649 -0.479 0.014 0.159 0.129 0.004 -0.004 -0.121 0.200 
Aperio % Fibrous 
Tissue 0.027 -0.307 -0.515 0.515 0.351 0.039 -0.114 -0.015 -0.002 0.002 0.075 -0.139 
Aperio % Fat -0.508 -0.604 -0.972*** 0.972*** 0.839** -0.237 -0.289 -0.566 -0.009 0.009 0.274 -0.383 
Aperio % 
Interstitial Space 0.283 -0.095 0.030 -0.030 -0.294 0.430 0.001 0.392 0.206 -0.206 -0.288 0.191 
Custom % Muscle 0.316 0.592 0.850** -0.850** -0.732* 0.012 0.355 0.414 0.192 -0.192 -0.202 0.148 
Custom % 
Fibrous Tissue 0.010 -0.383 -0.356 0.356 0.329 0.309 -0.349 -0.107 -0.408 0.408 0.017 0.245 
Custom % 
Interstitial Space 0.199 -0.118 0.292 -0.292 -0.403 0.751* -0.261 0.280 -0.204 0.204 -0.350 0.560 
Correlations in bold are significant at *p < 0.05, ** p < 0.01, *** p < 0.001 
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IV.5.2 Comparisons between histology segmentation methods 
Data from nine GRMD dogs evaluated in the histopathology portion of the study 
are summarized in table X.  Fat was manually segmented (SMB) using the Aperio software 
but the custom algorithm was unable to accurately differentiate fat from the interstitial 
space compartment.   
A Bland-Altman analysis indicated that the 95% limits of agreement between the 
Aperio segmentation and custom algorithm segmentation for the nine GRMD samples 
ranged from 2.98 to 18.45 for muscle (%), –1.49 to –22.10 for fibrous tissue (%), and 0.29 
to –17.82 for interstitial space (%) (Figure XIII).  Muscle and interstitial space (%) had 
fair to good relationships for ICC (ICC = 0.506; 0.427, respectively) while fibrous tissue 
(%) had a poor relationship for ICC (ICC = 0.261) (Figure XIV).   
While the values between methods for muscle and interstitial space had a good 
relationship, there were notable discrepancies between methods with the fibrous tissue 
compartment percentages differing by up to 22%.  The custom algorithm consistently 
overestimated the muscle (%) and underestimated the fibrous tissue (%) and interstitial 
space (%). 
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Table X.  Muscle, fibrous tissue, interstitial space, and fat values from Aperio and custom algorithm segmentation 
methods 
Dog 
Muscle (%) Fibrous Tissue (%) Interstitial Space (%) Fat (%) 
Aperio Custom Aperio Custom Aperio Custom Aperio Custom 
1 68.71 83.33 31.29 16.67 34.01 22.59 0.00 -- 
2 85.32 90.95 14.53 8.94 27.93 18.35 0.15 -- 
3 76.17 89.81 23.52 9.93 34.54 22.23 0.31 -- 
4 79.92 84.92 19.45 14.54 16.18 15.56 0.63 -- 
5 81.66 88.48 18.19 11.40 18.64 16.43 0.15 -- 
6 55.64 66.45 38.46 17.65 30.18 30.18 5.90 -- 
7 77.26 89.43 22.70 10.54 21.63 12.26 0.04 -- 
8 69.76 83.23 30.20 16.74 34.44 25.96 0.04 -- 
9 67.72 78.96 35.10 20.88 38.75 28.11 0.18 -- 
Mean 73.24 83.95 25.94 14.14 28.48 19.71 0.82 -- 
SEM 3.12 2.55 2.73 1.34 2.65 1.76 0.64 -- 
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Figure XIII.  Bland-Altman plots of measures from Aperio and custom algorithm segmentation methods.  A-C, Graphs 
show mean muscle (A), fibrous tissue (B), and interstitial space (C).  Each data point represents values from each animal 
measured. 
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Figure XIV.  Scatter plots of correlation between Aperio and custom algorithm segmentation measures.  A-C, Graphs 
show methods plotted (X, Y; Aperio, Custom) for muscle (A), fibrous tissue (B), and interstitial space (C), with intraclass 
correlation of coefficient (ICC) statistics included in each graph. 
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IV.5.3 Comparisons between MRI scanners 
The data from nine GRMD dogs evaluated in the MRI portion of the study and the 
values for T1, T2, water, fat, FA, and ADC from both the 4.7T and 3T scanners are 
summarized in table XI.   
A Bland-Altman analysis indicated that the 95% limits of agreement between the 
4.7T measures and 3T measures ranged from 167.16 to -168.43 for T1 (ms), 4.11 to 30.76 
for T2 (ms), 4.39 to -12.36 for water (%), 12.36 to -4.39 for fat (%), -0.34 to -0.36 for FA, 
and -0.17 to -0.40 for ADC (x 10-3 mm2/s) (Figure XV).  Only T1 had an excellent 
relationship for ICC (ICC = 0.792) while T2, water, fat, FA, and ADC all had poor 
relationships (ICC = 0.287; 0.081; 0.081; 0.041; 0.219, respectively) (Figure XVI).   
T1 is the only measure that appears to be a reliable between scanners while the 
other measures are all poorly correlated.  Additionally, none of the histology measures 
correlate with either T1 or any of the 3T MRI metrics. 
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Table XI.  T1, T2, water, fat, fractional anisotropy (FA), and apparent diffusion coefficient (ADC) values from 4.7T and 
3T MRI scans 
Dog 
T1 (ms) T2 (ms) Water (%) Fat (%) FA ADC (x10-3 mm2/s) 
4.7T 3T 4.7T 3T 4.7T 3T 4.7T 3T 4.7T 3T 4.7T 3T 
1 677.69 638.91 57.65 72.77 97.09 94.81 2.91 5.19 0.30 0.24 1.32 1.00 
2 512.72 513.04 49.86 71.82 97.25 94.76 2.75 5.24 0.29 0.14 1.45 1.20 
3 422.35 442.05 44.91 63.72 96.81 93.13 3.19 6.87 0.32 0.13 1.48 1.10 
4 319.81 316.33 37.39 49.33 94.96 85.30 5.04 14.70 0.47 0.18 1.45 1.20 
5 459.40 461.38 54.96 59.98 97.54 89.85 2.46 10.15 0.33 0.18 1.40 1.10 
6 323.03 405.25 35.75 52.13 90.03 92.80 9.97 7.20 0.53 0.19 1.32 1.00 
7 603.77 691.01 61.54 79.94 97.41 97.82 2.59 2.18 0.33 0.15 1.17 1.00 
8 380.68 421.59 48.36 68.63 97.00 92.66 3.00 7.34 0.33 0.16 1.50 1.20 
9 588.49 392.64 44.39 73.36 97.03 88.12 3.00 11.88 0.33 0.08 1.58 1.30 
Mean 476.44 475.80 48.31 65.74 96.12 92.14 3.88 7.86 0.36 0.16 1.41 1.12 
SEM 42.66 40.13 2.92 3.43 0.80 1.27 0.80 1.27 0.03 0.01 0.04 0.04 
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Figure XV.  Bland-Altman plots of measures from 4.7T and 3T MRI scanners.  A-E, Graphs show mean T1 (A), T2 (B), 
water (C), fat (D), fractional anisotropy (FA) (E), and apparent diffusion coefficient (ADC) (F).  Each data point 
represents values from each animal measured. 
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Figure XVI.  Scatter plots of correlation between measures with 4.7T and 3T MRI scanners.  A-E, Graphs show scanners 
plotted (X, Y; 4.7T, 3T) for  T1 (A), T2 (B), water (C), fat (D), fractional anisotropy (FA) (E), and apparent diffusion 
coefficient (ADC) (F) with intraclass correlation of coefficient (ICC) statistics included in each graph. 
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IV.6 Discussion 
The use of MRI as a biomarker in DMD has tremendous potential because it is 
non-invasive, quantifiable, and readily available in nearly all facets of human medicine.  
MRI has been used to evaluate patients with DMD dating back to the late 80’s [74, 204], 
extending to the use of quantitative parameters to characterize DMD progression in the 
early 90’s [205], and assessment of diffusion tensor imaging (DTI) more recently [90].  
Diagnosing DMD and evaluating new therapeutics relies heavily on results obtained from 
skeletal muscle biopsies.  Biopsies have generally been limited to large muscle groups in 
the thigh and arms as opposed to the more global and systematic assessment offered by 
MRI.  Direct correlation of quantitative histopathology and MR results would allow 
researchers to more accurately evaluate MR outcome parameters and thus more reliably 
assess the benefit of new therapeutics.   
 This study was multifactorial and focused primarily on three aims, 1) register and 
correlate corresponding histology and MR images of the pectineus muscle using a novel 
registration technique, 2) compare a commercially available histology segmentation 
program (Aperio) to a novel custom algorithm for automated histomorphometry, and 3) 
compare outputs from 4.7T research and 3T clinical scanners to determine potential 
clinical application of the registration techniques.  To the author’s knowledge, this is the 
first study to take this approach in either DMD or GRMD.  Several findings in this study 
were encouraging.  First, we were able to use a novel multi-step registration process to 
successfully align 2D histologic images of the pectineus muscle with the corresponding 
3D MR images similar to prior studies of prostate cancer [206, 207] and brain anatomy 
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[208, 209].  Importantly, these data establish a disease signature for use in clinical trials.  
However, clinical application of this technique will be limited by the long scan times 
required for high-resolution MR images.  Also, alignment of the five micrometers 
histology sections and 1-2 mm MR images was challenging.  This might be alleviated by 
using consecutive histology sections that equal MR image slice thickness.  Artifacts 
created in sectioning also caused tissue spacing that doesn’t exist on the MR image.  
Ideally, we would like to develop faster, lower resolution MRI sequences at 3T and 1.5T 
in vivo that could be compared to higher resolution MR and histologic images. 
 For the most part, we were unable to find significant correlations between 
measures from MR and histology images.  The Aperio segmented fat (%) strongly 
correlated with the 4.7T fat (%) and also with the FA.  But several studies evaluating 
skeletal muscle DTI have shown that low signal-to-noise ratio (SNR), water T2 value, and 
percentage fat composition can affect DTI parameters such as overestimating FA [210-
212].  Also, in a recent skeletal muscle DTI study in DMD patients they found that low 
SNR and percentage fat composition can falsely elevate FA [94].  Therefore validity of 
the FA correlation in this study should be investigated to determine if the SNR was 
acceptable.  MRI metrics have been successfully correlated to pathology in numerous 
brain injury studies, with FA decreasing in sync with white matter damage on histologic 
examination [213, 214].  ADC was shown to decrease with higher histopathologic fibrosis 
stages and also with higher necro-inflammatory grades [215].  The effects of pathology 
on MRI are complex, poorly understood, and could cancel each other out.  For example, 
 108 
 
fibrosis could reduce T2, fat deposition could increase T2, and they could average each 
other out so that T2 would not be helpful in staging disease progression.       
Confounding factors in this study could include a small sample size, large age 
distribution among the dogs resulting in various stages of disease progression (3 to 48 
months), large region of interest (ROI) analyzed, and volume averaging.  Muscle selection 
could also pose a problem.  We chose the pectineus muscle because it’s small and spherical 
making embedment manageable.  However, this muscle has only been minimally assessed 
in GRMD.  A relative lack of histopathologic involvement could have precluded lesion 
and MRI value correlation.  In vivo longitudinal evaluation of more commonly examined 
muscles such as the cranial sartorius and vastus lateralis could provide further insight.  
Additionally, instead of doing whole cross-sectional ROI’s, we could use many small 
ROI’s to more closely correlate MR and histology images.   
A second focal point of this study was to develop a custom automated algorithm.  
Traditional methods are labor intensive and can have high interobserver variability 
depending on the parameters assessed.  This could be resolved by automated 
histomorphometry using high resolution digital whole slide imaging and image analysis 
software.  Analogous techniques have been used for atherosclerotic histology [216], breast 
cancer [217], bone research [218] and skeletal muscle immunohistochemistry in mdx mice 
[219].  Since the custom algorithm consistently overestimated muscle and underestimated 
fibrous tissue compared to Aperio, we should reevaluate the histologic sections by 
manually grading these components to determine which method more closely identifies 
true pathology.  The custom algorithm also failed to reliably differentiate among fat, 
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interstitial space, and white space artifact on slides created when sectioning.  Further 
refinement and optimization of this algorithm can hopefully incorporate fat segmentation.  
There were several other limitations with our technique.  The algorithms in both 
segmentation models are based on color thresholds.  Variability among staining sessions 
could be countered by running all slides as a single batch.  Despite these limitations, we 
are encouraged and believe this novel segmentation method can be refined and applied to 
future DMD and GRMD research studies.   
Finally, the last aim in this study was to compare outputs from a 4.7T research 
scanner and a 3T clinical scanner.  We concluded that T1 values correlated between 
scanners but T2, water, fat, FA, and ADC values did not.  A study in 2007 compared FA 
in brain scans using 3T and 1.5T scanners and found significant differences between the 
machines [220].  Another study comparing 3T to 7T also found differences in FA and 
mean, radial, and axial diffusivity (MD/RD/AD).  The FA was dependent on location in 
the brain with 7T often giving higher FA values while the MD, RD, and AD were lower 
at 7T for most ROIs [221].  Therefore differences in magnet strength may make correlating 
DTI parameters (FA and ADC) difficult.  Differences between the water and fat are likely 
because the resolution for 3T is poor and thus the true fiber structure is not captured.  In 
most cases, the DTI and fat maps (provided by the scanner software) have low SNR 
resulting in values that should be interpreted carefully.  Another reason we may see poor 
correlation between the fat values is because these samples are very small and based on 
manual segmentation, most samples had very minimal fat.   
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Future studies will address full histologic examination of an entire muscle from 
end to end.  In this way, the segmental nature of dystrophic lesions can be better studied, 
allowing more precise correlation between histologic changes and MRI values.  In 
addition, the registration technique should be updated to account for registration of 
multiple five micrometer histologic sections and the algorithm should be optimized to 
segment fat.  Taken together, these improvements would facilitate a direct comparison 
between MR and histologic images.   
 In conclusion, our finding that MRI and histopathology can be directly correlated 
through a novel registration technique should improve image analysis in DMD and animal 
research.  We also showed that the two segmentation methods yielded similar results, 
suggesting that with further optimization, a fully automated algorithm could further 
enhance future histologic studies.  Finally, only T1 values from the 3T clinical scanner 
compared favorably to those from the 4.7T research scanner and none of the 3T values 
correlated with histopathology.  Detailed correlative studies between histopathology and 
MRI are imperative if MRI will be used as a biomarker of disease severity and treatment 
response in future studies involving DMD. 
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CHAPTER V  
CONCLUSIONS 
  
The three studies outlined in this dissertation show how important multiple 
imaging modalities are in identifying disease, evaluating disease progression, and in 
monitoring disease response to new treatments.  Technology continues to advance and 
with it comes better computers, better software, and better equipment that help us “view” 
the body from a perspective we once thought unimaginable.   
FASD is a devastating disease that continues to plague the U.S. despite our 
knowledge and education on the effects of alcohol use during pregnancy.  Because this 
problem continues today, we need better methods and techniques to identify affected 
children.  If children are identified at an early age, they could potentially be educated 
differently.  We know that sensitive brain structures responsible for behavior, attention, 
cognition, learning, memory, socioemotional function, and neurodevelopment among 
many others can all be affected with prenatal alcohol exposure.  MRI allows non-invasive, 
quantitative analysis of the brain, which is vital to characterizing the detrimental effects 
of this disease.  However, the use of animal models is necessary to control for variables 
and to be able to provide more detailed studies that can eventually be integrated into 
clinical evaluations.  The sheep model is an excellent large animal model because brain 
development in utero more closely mimic’s that of human brain development.   
The study outlined in chapter II showed how one CT scan could be used to perform 
quantitative evaluations in not only the soft tissue structures of the face, but also the 
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underlying bone.  We discovered that total bone volume is a more sensitive indicator than 
cranial circumference, which is a common measure used clinically in FAS and FASD.  We 
also discovered that the interorbital distance is highly significant in predicting alcohol 
exposed lambs and that this measure also correlates to the soft tissue intercanthal width 
measure.  These three measures, total skull bone volume, interorbital distance, and 
intercanthal width have not been described previously in human FASD studies.  Although 
the segmentation of total skull bone volume can be tedious, and CT is not likely to be used 
presently in children because of radiation exposure, as technology advances, safer CT 
scans and automated software are likely to be developed.   
Chapter III is an example of how new treatments need validation in animal guided 
studies prior to their use in human trials.  Choline supplementation is recommended during 
pregnancy for brain and spinal cord development but it is also being evaluated as an 
interventional strategy to counter the negatives effects of prenatal alcohol exposure in 
women during pregnancy.  This is important for several reasons.  First, some women drink 
unknowingly during their first trimester because they don’t know they are pregnant.  We 
know that sensitive structures in the brain and spinal cord formed during the first trimester 
can be adversely affected by alcohol exposure.  An interventional strategy given at this 
time may help ameliorate potential negative outcomes associated with exposure.  Second, 
some women are alcoholics and will continue to drink regardless of whether they are 
pregnant.  To successfully implement interventional strategies, extensive animal model 
studies should first validate their safety and efficacy prior to human use.  In human and 
rodent studies of FASD, choline has been shown to improve memory and learning deficits 
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but minimal work has been done looking at structural brain benefits.  In our study we 
showed binge like alcohol administered prenatally during the first trimester equivalent 
causes brain volume reductions in peripubertal lambs that this failed to resolve when ewes 
were administered a choline supplement throughout pregnancy.  Although we did not test 
for behavioral associated benefits, brain volume was still reduced with or without choline 
supplementation.  This finding has not been described previously either in the sheep model 
of FASD or the human literature.   
Finally, chapter IV focused on correlating quantitative imaging with 
histopathology in the golden retriever model of DMD.  DMD is an X-linked recessive 
disorder, primarily of boys, caused by mutations in the dystrophin gene resulting in 
progressive muscle wasting and replacement by fat and fibrous tissue.  Boys are often 
wheelchair bound by their early teens die from cardiopulmonary complications by their 
late 20s to early 30s.  There is no cure for DMD so the pursuit of new treatments is 
constant.  While skeletal muscle biopsies are considered a “gold standard” in 
characterizing DMD, the procedure further compromises DMD boys who are already 
fragile and lack adequate muscle mass.  Accordingly, there is a push to develop non-
invasive, quantitative imaging techniques.  In this study, we had three central aims, 1) 
register and correlate corresponding histology and MR images of the pectineus muscle 
using a novel registration technique, 2) compare a commercially available histology 
segmentation program (Aperio) to a novel custom algorithm for automated 
histomorphometry, and 3) compare outputs from 4.7T research and 3T clinical scanners 
to determine potential clinical application of the registration techniques.  We found that 
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histology and MR images co-registered but metrics were poorly correlated.  The Aperio 
software provided similar results to the custom algorithm and with further optimization, a 
fully automated algorithm could be applied to the current research.  Only T1 values were 
correlated between the 4.7T or 3T scanners.  Neither T1 values, nor any of the 3T metrics 
correlated with histologic segmentations.  Future studies in this area will focus on a full 
histologic examination of an entire muscle from end to end so that the segmental nature 
of dystrophic lesions can be better characterized in image correlation.  
The FASD and DMD studies outlined here are examples of how advanced imaging 
techniques could be applied, potentially with modification, to characterize numerous 
diseases.  The training I received during my PhD provides me with special insight on the 
integration of imaging modalities, quantitative techniques, and pathology.  This unique 
niche will make me valuable as a veterinary anatomic pathologist, independent biomedical 
researcher, and professor. 
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